

Exercise for type 2 diabetes mellitus (Review)

Thomas DE, Elliott EJ, Naughton GA



**THE COCHRANE
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2007, Issue 1

<http://www.thecochranelibrary.com>



TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	1
BACKGROUND	2
OBJECTIVES	3
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW	3
SEARCH METHODS FOR IDENTIFICATION OF STUDIES	4
METHODS OF THE REVIEW	4
DESCRIPTION OF STUDIES	6
METHODOLOGICAL QUALITY	8
RESULTS	8
DISCUSSION	11
AUTHORS' CONCLUSIONS	13
POTENTIAL CONFLICT OF INTEREST	13
ACKNOWLEDGEMENTS	13
SOURCES OF SUPPORT	13
REFERENCES	14
TABLES	16
Characteristics of included studies	16
Characteristics of excluded studies	24
ADDITIONAL TABLES	25
Table 01. Search strategy	25
Table 02. Study Quality	27
Table 03. Quorum Diagramme	27
Table 04. Original data	28
Table 05. Original data (continued)	31
ANALYSES	32
Comparison 01. Exercise vs no exercise	32
INDEX TERMS	33
COVER SHEET	33
GRAPHS AND OTHER TABLES	34
Analysis 01.01. Comparison 01 Exercise vs no exercise, Outcome 01 Glycated haemoglobin (%)	34
Analysis 01.02. Comparison 01 Exercise vs no exercise, Outcome 02 Visceral adipose tissue (cm ²)	35
Analysis 01.03. Comparison 01 Exercise vs no exercise, Outcome 03 Subcutaneous adipose tissue (cm ²)	35
Analysis 01.04. Comparison 01 Exercise vs no exercise, Outcome 04 Body Mass (kg)	36
Analysis 01.05. Comparison 01 Exercise vs no exercise, Outcome 05 Triglycerides (mmol/litre)	36
Analysis 01.06. Comparison 01 Exercise vs no exercise, Outcome 06 Maximal exercise capacity (VO ₂ max)(ml/(kg*min))	37
Analysis 01.07. Comparison 01 Exercise vs no exercise, Outcome 07 Systolic blood pressure (mmHg)	37
Analysis 01.08. Comparison 01 Exercise vs no exercise, Outcome 08 Diastolic blood pressure (mmHg)	38
Analysis 01.09. Comparison 01 Exercise vs no exercise, Outcome 09 Fasting plasma glucose concentration (mmol/L)	38
Analysis 01.10. Comparison 01 Exercise vs no exercise, Outcome 10 Insulin (fasting concentration (pmol/litre)	39
Analysis 01.11. Comparison 01 Exercise vs no exercise, Outcome 11 Body Mass index (kg/m ²)	39
Analysis 01.12. Comparison 01 Exercise vs no exercise, Outcome 12 Total cholesterol (mmol/l)	40
Analysis 01.13. Comparison 01 Exercise vs no exercise, Outcome 13 HDL-cholesterol (mmol/l)	40
Analysis 01.14. Comparison 01 Exercise vs no exercise, Outcome 14 LDL-cholesterol (mmol/l)	41

Exercise for type 2 diabetes mellitus (Review)

Thomas DE, Elliott EJ, Naughton GA

This record should be cited as:

Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* 2006, Issue 3. Art. No.: CD002968. DOI: 10.1002/14651858.CD002968.pub2.

This version first published online: 19 July 2006 in Issue 3, 2006.

Date of most recent substantive amendment: 24 May 2006

ABSTRACT

Background

Exercise is generally recommended for people with type 2 diabetes mellitus. However, some studies evaluate an exercise intervention including diet or behaviour modification or both, and the effects of diet and exercise are not differentiated. Some exercise studies involve low participant numbers, lacking power to show significant differences which may appear in larger trials.

Objectives

To assess the effects of exercise in type 2 diabetes mellitus.

Search strategy

Trials were identified through the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and manual searches of bibliographies. Date of last search was March 3, 2005.

Selection criteria

All randomised controlled trials comparing any type of well-documented aerobic, fitness or progressive resistance training exercise with no exercise in people with type 2 diabetes mellitus.

Data collection and analysis

Two authors independently selected trials, assessed trial quality and extracted data. Study authors were contacted for additional information. Any information on adverse effects was collected from the trials.

Main results

Fourteen randomised controlled trials comparing exercise against no exercise in type 2 diabetes were identified involving 377 participants. Trials ranged from eight weeks to twelve months duration. Compared with the control, the exercise intervention significantly improved glycaemic control as indicated by a decrease in glycated haemoglobin levels of 0.6% (-0.6 % HbA_{1c}, 95% confidence interval (CI) -0.9 to -0.3; $P < 0.05$). This result is both statistically and clinically significant. There was no significant difference between groups in whole body mass, probably due to an increase in fat free mass (muscle) with exercise, as reported in one trial (6.3 kg, 95% CI 0.0 to 12.6). There was a reduction in visceral adipose tissue with exercise (-45.5 cm², 95% CI -63.8 to -27.3), and subcutaneous adipose tissue also decreased. No study reported adverse effects in the exercise group or diabetic complications. The exercise intervention significantly increased insulin response (131 AUC, 95% CI 20 to 242) (one trial), and decreased plasma triglycerides (-0.25 mmol/L, 95% CI -0.48 to -0.02). No significant difference was found between groups in quality of life (one trial), plasma cholesterol or blood pressure.

Authors' conclusions

The meta-analysis shows that exercise significantly improves glycaemic control and reduces visceral adipose tissue and plasma triglycerides, but not plasma cholesterol, in people with type 2 diabetes, even without weight loss.

PLAIN LANGUAGE SUMMARY

Exercise for type 2 diabetes mellitus improves blood sugar control and decreases body fat content

Exercise for type 2 diabetes mellitus (Review)

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd

Exercise, dietary changes and medications are frequently used in the management of type 2 diabetes. However, it is difficult to determine the independent effect of exercise from some trials because exercise has been combined with dietary modifications or medications, or compared with a control which includes another form of intervention. The review authors aimed to determine the effect of exercise on blood sugar control in type 2 diabetes.

This review found that exercise improves blood sugar control and that this effect is evident even without weight loss. Furthermore, exercise decreases body fat content, thus the failure to lose weight with exercise programmes is probably explained by the conversion of fat to muscle. Exercise improved the body's reaction to insulin and decreased blood lipids. Quality of life was only assessed in one study, which found no difference between the two groups. No significant difference was found between groups in blood levels of cholesterol or blood pressure. A total of 14 randomised controlled trials were assessed. These included 377 participants and compared groups that differed only with respect to an exercise programme intervention. The duration of the interventions in the studies ranged from eight weeks to one year. Two studies reported follow-up information, one at six months after the end of the six month exercise intervention and one at twelve months post-intervention. Generally, the studies were well-conducted, but blinding of outcome assessors was not reported and although all studies reported that randomisation was performed, few gave details of the method.

No adverse effects with exercise were reported. The effect of exercise on diabetic complications was not assessed in any of the studies.

The relatively short duration of trials prevented the reporting of any significant long term complications or mortality. Another limitation was the small number of participants included in the analyses for adiposity, blood pressure, cholesterol, body's muscle and quality of life.

BACKGROUND

Diabetes mellitus is a metabolic disorder resulting from defective insulin secretion, insulin action, or both. A consequence of this is chronic hyperglycaemia (that is elevated levels of plasma glucose) with disturbances of carbohydrate, fat and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy and neuropathy and increased risk of cardiovascular disease. For a detailed overview of diabetes mellitus, please see 'Additional information' provided by the Metabolic and Endocrine Disorders Group in *The Cochrane Library* (see 'About The Cochrane Collaboration', 'Collaborative Review Groups'). For an explanation of methodological terms, see the main Glossary in *The Cochrane Library*.

Exercise

In non-diabetic participants, studies have shown that exercise reduces hyperglycaemia, insulin resistance, hypertension and dyslipidaemia, and provides a protective effect against cardiovascular disease (ADA 1997; Bouchard 1994; Després 1997; Kelley 1995; NIH 1998; Shaw 2001). Exercise, in addition to diet modification and medication, has long been recommended as one of the three main components to diabetic therapy (Joslin 1959). People with type 2 diabetes are encouraged to increase physical activity, because studies in people without diabetes suggest it may reduce hyperglycaemia and body fat and improve protection against developing cardiovascular complications. The low cost and non-pharmacological nature of exercise enhances its therapeutic appeal.

Even though exercise is recommended as part of diabetic therapy, its effects in type 2 diabetes are not well documented and there have been no large studies with adequate statistical power to guide

practitioners in recommending exercise programmes for the management of type 2 diabetes. Published exercise intervention trials, using different types of intervention, usually have small sample sizes since they are difficult and expensive to conduct. The findings have varied.

The optimal type, frequency, intensity and duration of exercise for achieving therapeutic goals in type 2 diabetes are not known. Aerobic exercise, which is the repetitive cyclical movements caused by contraction of the large muscle masses relying on aerobic energy pathways, is the usual intervention in exercise studies. In aerobic exercise, the muscular and cardiorespiratory systems are involved (for example brisk walking, cycling, swimming, and jogging). Resistance training, which is exercise using muscular strength to move a weight or to work against a resistive load (for example exercise with free weights or weight machines) may also be used as an intervention. Resistance training increases muscle strength and size when performed regularly at a sufficient intensity.

In type 2 diabetes, the promotion of weight loss is one mechanism through which exercise may be beneficial (Ivy 1997; Wallberg-H. 1998) since obesity, especially abdominal obesity, is associated with metabolic abnormalities in diabetes. However, studies in both diabetic and non-diabetic people demonstrate that, even without any weight loss, exercise may still be beneficial. For example, a single bout of exercise lowers plasma glucose levels and increases insulin sensitivity (Wallberg-H. 1998). Insulin sensitivity can be measured, using radioimmunoassay, over the period of a three hour oral glucose tolerance test, with blood specimens being tested every half hour (Tessier 2000). The incremental area under the insulin curve thus obtained indicates the degree of insulin sensitivity. The adaptations to a single bout of exercise are short lived (King 1995)

and some of the benefits from exercise training may be due to the repeated acute improvements which follow individual exercise sessions (Albright 2005).

Exercise is usually a general recommendation prescribed for people with type 2 diabetes, especially in the early stages. The longer the disease has been present, the greater likelihood there is of disease complications, which may limit exercise. Possible adverse effects of exercise in people with type 2 diabetes mellitus may include an abnormal cardiovascular response to exercise or problems related to foot care (Constantini 2005). Exercise capabilities may be limited by the presence of retinopathy, neuropathy or nephropathy.

In a review of different weight loss strategies in type 2 diabetes (Brown 1996), the effect of aerobic exercise on diabetic control was reported. Of the 89 studies included, 10% had exercise interventions, but only five studies had a control group. It was concluded that exercise caused a reduction in glycated haemoglobin and a decrease in body mass. A meta-analysis of controlled clinical trials (Boule 2001) addressed the effect of exercise on glycaemic control and body mass in type 2 diabetes and concluded that exercise training reduces glycated haemoglobin, but not body mass. However, Boule et al included some non-randomised controlled trials, and also some trials in which diet was a co-intervention with exercise in the intervention group, while the same diet was not also applied to the control group. Hence, it was not possible to measure the effects of the exercise per se.

The object of this systematic review was to explore the independent effect of exercise in people with type 2 diabetes. All randomised controlled trials in which the only difference between the intervention group and the comparison group was that the intervention group performed well-documented exercise were included. Our review included a range of outcome measures. We assessed the effects of different types of exercise interventions by performing subgroup analyses, to provide explanations for variations found in individual trials and evaluated the scientific evidence to support or refute the role of exercise interventions.

OBJECTIVES

To assess the effects of exercise in type 2 diabetes mellitus.

CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

Types of studies

Inclusion criteria

(1) Trial design

We considered all randomised controlled trials (RCT) comparing aerobic, fitness or progressive resistance training exercise with no exercise in type 2 diabetes mellitus.

(2) Trial duration

We included trials of eight weeks or longer, because we wanted to evaluate the effect of ongoing exercise training rather than acute single bouts of exercise. A training period of less than eight weeks would be too short to show alteration in either glycated haemoglobin concentrations or body mass. A post-intervention follow-up of at least six months would have been ideal to specify also, however this was not an absolute criterion for study inclusion.

Exclusion criteria

Single bout exercise interventions; studies where the intervention involved only the recommendation of increased physical activity, without further detail; studies where the exercise intervention was not either directly supervised or well-documented; studies where there was a co-intervention in the experimental group such as a dietary alteration or counselling that was not also applied to the control group.

Studies where the same diet was applied to both the intervention group and the control group and hence the exercise in the intervention group was the only difference between the two groups, were not excluded.

Types of participants

The participants were males and females with type 2 diabetes. Ideally, the diagnostic criteria for type 2 diabetes mellitus should have been described in the trial. To be consistent with changes in classification and diagnostic criteria of diabetes through the years, the diagnosis should have been established using the standard criteria valid at the beginning of the trial. Acceptable diagnostic criteria included those described by: the National Diabetes Data Group standards (NDDG 1979), the World Health Organisation standards (WHO 1980; WHO 1999) or the American Diabetes Association standards (ADA 1997b). The major difference between the different standards is that the ADA cutoff point for diabetes is a fasting blood glucose level of equal to or more than 7.0 mmol/L whereas the other two standards use a cutoff of equal to or more than 7.8 mmol/L. Changes in diagnostic criteria may have produced variation in the clinical characteristics of the people included in trials as well as in the results obtained.

Studies performed on people with impaired glucose tolerance (IGT) were not included in the analysis. Where studies reported the combined results for people with type 2 diabetes and IGT, we contacted the authors requesting individual data. If these data were not provided, the trial was excluded.

Types of intervention

The included studies prescribed an exercise intervention, defined as a pre-determined program of physical activity. Physical activity can comprise any body movement produced by skeletal muscle, resulting in an increase in energy expenditure. In contrast, exercise prescriptions include specific recommendations for the type, intensity, frequency and duration of physical activity with a spe-

cific objective (that is, increase fitness or health) (Bouchard 1994). Studies that stated they simply recommended increasing physical activity were not included in the analyses unless it was possible to quantify the exercise stimulus.

We intended to measure the effect of exercise, hence only included studies where the only difference in interventions between groups was exercise. Using this inclusion criteria, studies involving dietary or medication changes were eligible for inclusion only when the same treatments were applied to both the control and intervention groups. The review includes studies involving three types of intervention:

- (1) exercise versus non-exercise control;
- (2) exercise plus diet versus diet alone;
- (3) exercise plus medication versus medication alone.

Types of outcome measures

Primary outcomes

- (1) glycaemic control measured as percent glycated haemoglobin (HbA_{1c}) (or fasting glucose concentration, glucose tolerance test, post prandial blood glucose);
- (2) body mass indices (body mass (kg), body mass index (BMI) (kg/m²), visceral adipose tissue (cm²), subcutaneous adipose tissue (cm²), muscle mass (kg));
- (3) adverse events (hypoglycaemic reactions, exercise induced injuries).

Secondary outcomes

- (1) insulin sensitivity (area under the insulin curve, Kitt constant, plasma insulin concentrations);
- (2) blood lipids (mmol/litre): total cholesterol, high density lipoprotein-cholesterol (HDL), low-density lipoprotein-cholesterol (LDL), triglycerides;
- (3) blood pressure (mmHg);
- (4) quality of life (using validated instruments such as SF-36, Euroqol);
- (5) fitness (as measured by maximal exercise capacity (VO_{2max}));
- (6) diabetic complication rates (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy and diabetic cardiovascular disease);
- (7) mortality.

This review focused on clinically important outcomes, measured using physiological variables associated with diabetes and its complications. The secondary outcomes hyperinsulinaemia dyslipidaemia and hypertension are also associated with cardiovascular disease (Bouchard 1994; Després 1997; Lamarche 1998; Yki-Yarvinen 1998). Knowledge of the effects of exercise on these variables is important since people with type 2 diabetes have morbidity and mortality rates from cardiovascular disease two to four fold higher than people without diabetes (Meltzer 1998).

Timing of outcome assessment (length of intervention)

Studies were classified as short term (less than three months), medium term (three to less than six months), long term (6 to 12

months) and over 12 months duration, according to the timing of the outcome assessments measured at the end of the intervention.

SEARCH METHODS FOR IDENTIFICATION OF STUDIES

See: Cochrane Metabolic and Endocrine Disorders Group methods used in reviews.

Electronic searches

We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2005), MEDLINE and EMBASE were searched from January 1966 (when possible) to March 2005, using the search strategy specified in Table 01 of the Additional tables. We placed no language restrictions on either the search or the included trials.

Handsearching

The reference lists of review articles and included studies were handsearched for other potentially eligible studies.

METHODS OF THE REVIEW

Trial selection

To determine the studies to be assessed, two authors (DT and GN) independently reviewed the titles, abstract sections and keywords of every record retrieved from the search. The full articles were retrieved for further assessment when the information suggested that the study may fit the review criteria. Any trial that clearly did not fulfil the selection criteria, for example, the participants did not have type 2 diabetes mellitus, there was no control group, the trial included a co-intervention which was not also applied to the control group or the trial only measured the acute effect of a single exercise session, was eliminated. From the full articles of the remaining studies, the decision to eliminate a trial was based on agreement by all three authors. When a trial was excluded after this, a record of the article, including the reason for exclusion, was retained (table: Characteristics of excluded trials). We had planned to measure inter-rater agreement using Cohen's kappa statistic (Fleiss 1981) and to discuss any differences in opinion with a third party. However, as the authors were unanimous in their initial choices of abstracts for further investigation, this was not done.

Quality assessment of trials

The quality of each included randomised controlled trial was assessed independently by two authors (DT and GN), based on quality criteria specified by Schultz and Jadad (Jadad 1996; Schultz 1995). The following factors were studied:

- (1) Minimisation of selection bias - a) was the randomisation procedure adequate? b) was the allocation concealment adequate?

(2) Minimisation of attrition bias - a) were withdrawals and dropouts completely described? b) was the analysis by intention-to treat?

(3) Minimisation of detection bias - were the outcome assessors blind to the intervention?

Blinding of the people administering the intervention, as well as the participants actually doing the exercise is impossible in exercise intervention trials, so only the blinding of outcome assessors was assessed.

We had planned a sensitivity analysis based on classification of the studies into three categories (*Cochrane Handbook for Systematic Reviews of Interventions*):

A - low risk of bias: all quality criteria met;

B - moderate risk of bias: one or more of the quality criteria only partially met;

C - high risk of bias: one or more quality criteria not met, as well as exploring the effect of the individual quality criteria. However, as there were insufficient data, this was not done.

We assessed each trial independently for quality, and for any differences of opinion we had planned to calculate the level of inter-rater agreement using the kappa statistic (Fleiss 1981), resolving the differences by discussion. However, there was no disagreement on quality assessment.

Data extraction

Two authors (DT and GN) independently extracted the data on study population, intervention and outcome in each included study, using a standard data extraction form, which included the following:

(1) General information: published/unpublished, title, authors, source, contact address, country, setting, language, year of publication, duplicate publication, source of funding;

(2) Trial characteristics: design, randomisation (and method if stated), allocation concealment, blinding of outcome assessors;

(3) Participants: if randomised, inclusion criteria, exclusion criteria, total number in intervention/control groups, sex, age, baseline characteristics, diagnostic criteria, similarity of groups at baseline, withdrawals/losses to follow-up;

(4) Intervention and comparator, duration of trial;

(5) Outcomes: Outcomes specified in the methods, other outcomes assessed, length of post-intervention follow-up if applicable;

(6) Results: For continuous variables, we extracted the number of participants, and the baseline and post-intervention means with standard deviations (SD) (or standard error of the mean (SEM) or 95% confidence interval (95% CI)) for the intervention and control groups. We transformed SEM or 95% CI into SD, if appropriate. There were no relevant dichotomous variable outcomes.

Variations in data extraction were resolved by consensus, referring back to the original data.

We contacted three authors, two for clarification and one to request raw data.

When data were available only in graph form, the best estimate of the mean and SD was obtained. When post-intervention measures of dispersion (SD, SEM or 95% CI) were not available (for example when post-intervention information was expressed as percentage change from baseline values) the measure of dispersion at baseline was used as the post-intervention value. However, this extrapolation was only performed when other pre- and post-measures of dispersion were similar for the same outcomes in other trials. Variation at baseline should be greater than at post-intervention, hence any such replacement should be conservative.

Data analysis

Data were summarised statistically, when they were sufficiently uniform and of sufficient quality.

For continuous outcomes, weighted mean differences (WMD) between the post-intervention values of the intervention and control groups were used to analyse the size of the intervention effects. When the information was provided, we used an intention-to treat analysis. If results for continuous outcomes had been presented on different scales, we had planned to use standardised mean differences (SMD).

All data were initially analysed with a fixed effect model. We tested for heterogeneity between trial results using a standard chi-squared test to observe whether any variation in study results was compatible with the variation expected by chance alone. A significance level of $\alpha = 0.1$ was used for the test of heterogeneity. The I^2 parameter was used to quantify any inconsistency ($I^2 = [(Q-df)] \times 100\%$, where Q is the chi-squared statistic and df is its degrees of freedom) (Higgins 2003). A value for I^2 greater than 50% was considered to be substantial heterogeneity. Where heterogeneity was found, we attempted to determine potential sources of heterogeneity with various subgroup and sensitivity analyses.

Subgroup analyses

We performed length of intervention subgroup analyses excluding the longest study and the two longest studies for our main outcome, glycated haemoglobin, as there were sufficient data for this (less than three months, three to less than six months, six to twelve months and over twelve months). Other subgroup analyses planned, but with insufficient data to pursue were: age (less than 18 years, 18 to 45 years, older than 45 years), sex (male or female), body mass (body mass index less than 25, over 25), medication (receiving medication, not receiving medication), post-intervention follow-up timing (less than six months, six to twelve months, more than twelve months), the type of exercise intervention (aerobic or non-aerobic), exercise frequency (less than three times per week, more than three times per week).

Sensitivity analyses

We had proposed to perform sensitivity analyses to explore the influence of a number of other factors on effect size, by repeating the analysis:

- (1) excluding unpublished studies;
- (2) taking study quality, as specified above, into account;
- (3) excluding any large studies to establish how much they dominated the results;
- (4) excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.

Assessment of publication bias

We assessed funnel plot asymmetry to explore bias (Cooper 1994).

DESCRIPTION OF STUDIES

From the initial search, 2101 records were identified, and from these, 98 full papers were identified for further examination. The other studies were excluded on the basis of their abstracts because they were not relevant to the question under study. Main reasons for exclusion were: exercise was not the sole intervention, articles were reviews, studies did not compare similar groups, (for example only one group had type 2 diabetes, all participants did not have type 2 diabetes, or participants with type 2 diabetes were indistinguishable from those with impaired glucose tolerance), the intervention was less than eight weeks, the paper was on prevention rather than treatment of type 2 diabetes or the study had no control group, no randomisation, or else insufficient data were provided (Kaplan 1985; Kaplan 1987). See Table 03 for details of the amended Quorum statement.

From 35 potentially appropriate papers selected for closer examination, 14 studies finally met the inclusion criteria. Two studies (Mourier 1997; Ronnema 1986) reported results through two papers.

Assessment of publication bias inter-rater agreement

Two authors (DT and GN) reviewed the studies. There was agreement on the studies to be extracted for closer inspection from the searches. The full papers were obtained, and from these, the studies eligible for the review were selected. All three authors agreed on the final papers chosen for the review.

Missing data

Three authors were contacted for further information. Professor Sato was contacted for clarification on whether the participants had been randomised in the Yamanouchi 1995 study. We received a rapid response, confirming that the trial had been a controlled clinical trial and randomisation had not been possible under the circumstances. We also contacted Bogardus 1984, to ask if they had separate data for type 2 diabetes and impaired glucose tolerance (IGT) participants, since these are combined in the paper and impaired glucose tolerance was one of our exclusion criteria. We received an efficient response informing us that no raw data for

this trial were available. These studies are included in the 'Characteristics of excluded studies' table.

Excluded studies

Excluded studies and the reasons for excluding them are given in the Table: 'Characteristics of excluded studies'.

Included studies

Details of the characteristics of the included studies are given in the Table: 'Characteristics of included studies'. The following gives a brief overview.

Study types

All final 14 studies selected for the review were randomised controlled trials. They were conducted in Australia (Dunstan 1998; Dunstan 2002; Maiorana 2002), Canada (Cuff 2003; Tessier 2000), Denmark (Dela 2004), Finland (Loimaala 2003; Ronnema 1986), France (Mourier 1997), Israel (Raz 1994), Japan (Tsujiuchi 2002), New Zealand (Baldi 2003), and USA (Wing 1988b; Yeater 1990). The duration of the interventions ranged from eight weeks in four studies (Dunstan 1998; Maiorana 2002; Mourier 1997) to one study using six months (Samaras 1997) to 12 months (Loimaala 2003). One trial had a post-intervention follow-up at 12 months after the end of the 12 week intervention (Raz 1994). Another trial (Wing 1988b) reported data from a one-year follow-up, but not as the exercise group versus the control group, rather as the self-reporting of exercise from all the participants available in the trial. The shorter studies mainly involved progressive resistance training (Dunstan 1998; Maiorana 2002; Mourier 1997) and the exercise prescription in longer studies tended to involve moderate aerobic exercise such as walking (Tessier 2000) or cycling (Raz 1994) or controlled endurance training combined with muscle strength training (Loimaala 2003).

Participants

The included studies involved 377 participants. The number of participants in a single study ranged from 16 (Dela 2004; Yeater 1990) to 49 (Loimaala 2003) with a pooled total of 361 participants in studies reporting glycated haemoglobin. Of these, 198 participants received the exercise intervention. Only six studies (Baldi 2003; Cuff 2003; Dunstan 2002; Loimaala 2003; Raz 1994; Tessier 2000) included more than 16 participants in the intervention group, one having 24 (Loimaala 2003). The mean age of most groups was between 45 (Mourier 1997) and 65 (Tessier 2000) years and slightly more men than women participated. No study included children.

Interventions

Duration

Exercise interventions ranged from eight weeks duration (Dunstan 1998; Maiorana 2002; Mourier 1997; Yeater 1990) to one year (Loimaala 2003). Two trials (Raz 1994; Wing 1988b) reported post-intervention follow-up results, Raz et al at six months after the end of the six month intervention and Wing et al at 12 months post-intervention. The most common duration of the intervention

was either eight weeks (Dunstan 1998; Maiorana 2002; Mourier 1997; Yeater 1990) or 16 weeks (Cuff 2003; Ronnema 1986; Tessier 2000; Tsujiuchi 2002). In two studies the intervention was 10 weeks, (Baldi 2003; Wing 1988b), in two studies over 12 weeks (Dela 2004; Raz 1994) and in one study over 24 weeks (Dunstan 2002). One intervention lasted 52 weeks (Loimaala 2003).

The duration of individual exercise sessions varied from at least 30 minutes for resistance training (Dela 2004; Loimaala 2003) to 120 minutes for a Qi Gong program (Tsujiuchi 2002). Approximately 60 minutes duration per exercise session was cited in seven studies. The number of weekly sessions in the interventions varied from one (Tsujiuchi 2002) to seven (Ronnema 1986). Individual details are provided in the table of 'Characteristics of included studies'. The Mourier 1997 study had a design that enabled two sets of comparison groups within the one study.

Frequency

Most interventions involved three sessions per week with exercise occurring on non-consecutive days. This accords with recovery and adaptation principles of exercise programming. One recent study using Qi Gong involved one two-hour session per week (Tsujiuchi 2002). Two studies required participants to complete one unsupervised session in addition to the three (Loimaala 2003; Wing 1988b) or two (Raz 1994) sessions supervised by researchers. Compliance with exercise five or more times per week was required in two studies (Dela 2004; Ronnema 1986). One of these five weekly sessions studies (Dela 2004) was home-based rather than community based with compliance monitored using hidden counters on the cycle ergometers.

Types of exercise

The studies in this systematic review included various types of exercise interventions, both resistance and aerobic based. In some of the studies using aerobic training programmes, a choice of aerobic activities was made available to participants (Raz 1994; Ronnema 1986; Yeater 1990). In some trials, additional unsupervised exercise sessions were also included (Loimaala 2003; Raz 1994; Wing 1988b). In one study, the use of hidden counters on the cycle ergometers was a novel way of supervision and effectively measured compliance (Dela 2004). In the studies using progressive resistance training, the loads imposed in recent trials (Dunstan 2002; Loimaala 2003) were higher than in other trials (Dunstan 1998; Tessier 2000). Usually loads are lighter for the first two weeks, after which they are increased (Baldi 2003; Dunstan 1998; Dunstan 2002; Mourier 1997). In some studies, re-assessment of progression in resistance training programmes was routine (Dunstan 1998; Loimaala 2003). In other trials, progression was determined on an individual goal attainment basis (Baldi 2003; Dunstan 2002). Detailed descriptions of the exact resistance training regimes used in more recent studies mean that these could be accurately duplicated (Cuff 2003; Dunstan 2002). One study provided the control group with short supervised stretching regimes (Dunstan 2002).

Intensity of exercise intervention

Traditionally interventions were either progressive resistance training (Dunstan 1998) or moderate aerobic training (Baldi 2003; Mourier 1997; Raz 1994; Wing 1988b; Yeater 1990). Longer trials involved combinations of progressive resistance and at least some aerobic training (Cuff 2003; Dela 2004; Dunstan 2002; Loimaala 2003). Progressive resistance training prescriptions have been described with increasing accuracy over the past two decades and more recent studies describe the precise regime and duration of intervals between sets as well as the frequency of re-testing during the trials (Cuff 2003; Dunstan 2002).

Percentage of the maximal oxygen uptake (Ronnema 1986; Tessier 2000), peak oxygen uptake (Mourier 1997), or peak heart rate (Maiorana 2002) were scales used to define the percentage effort required in the interventions. Exercise modalities included continuous and intermittent cycling (Mourier 1997), progressive increases in walking (Dela 2004; Tessier 2000; Yeater 1990) and mixed aerobic sessions of running, cycling, skiing, and swimming (Raz 1994; Ronnema 1986). Among more recent studies, mixed aerobic and resistance training sessions were prescribed (Cuff 2003; Loimaala 2003; Maiorana 2002; Tessier 2000). One study prescribed a two hour session of Qi-gong (Tsujiuchi 2002).

Outcomes

Original data can be found in Table 04 and Table 05.

Primary outcome measures

Glycaemic control

Glycated haemoglobin was used as the principal measure for glycaemic control in this review (Peters 1996). All 14 studies measured glycated haemoglobin, involving a total of 377 participants. There were 361 participants in the meta-analysis (Baldi 2003; Cuff 2003; Dela 2004; Dunstan 1998; Dunstan 2002; Loimaala 2003; Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Tessier 2000; Tsujiuchi 2002; Wing 1988b) and 16 participants in the Yeater 1990 study, which, while described as a randomised controlled trial, provided no data for the control group and so could not be included in the meta-analysis.

Other measures relating to plasma glucose concentrations that were reported were fructosamine (Raz 1994), fasting plasma glucose concentration and AUC (area under the curve) glycaemia (Tessier 2000). Nine studies measured fasting plasma glucose concentration (Baldi 2003; Dela 2004; Dunstan 1998; Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Tessier 2000; Wing 1988b). One study reported results of oral glucose tolerance tests (Ronnema 1986).

Body mass index

Ten studies (n = 248) reported results for body mass (Baldi 2003; Cuff 2003; Dela 2004; Dunstan 1998; Dunstan 2002; Maiorana 2002; Mourier 1997; Ronnema 1986; Tessier 2000; Wing 1988b) and five of these studies also included body mass index (BMI) (Dela 2004; Dunstan 1998; Maiorana 2002; Mourier

1997; Tessier 2000). One study (Yeater 1990) reported that body mass did not change but gave no data. Two studies (Loimaala 2003; Raz 1994) included only body mass index. One study (Baldi 2003) reported both fat free mass (a measure of musculoskeletal mass) and fat mass. Two studies reported visceral and subcutaneous adipose tissue (Cuff 2003; Mourier 1997).

Adverse effects

No study included adverse effects as an outcome.

Secondary outcome measures

Insulin sensitivity

Insulin sensitivity was reported in a number of ways. Only one study (Tessier 2000) reported area under the insulin curve. One study reported the KITT constant, related to the insulin tolerance test (Mourier 1997). Seven studies reported fasting insulin concentration (Baldi 2003; Dela 2004; Dunstan 1998; Mourier 1997; Ronnema 1986; Tessier 2000; Wing 1988b) and one further study (Yeater 1990) also investigated fasting insulin concentration, mentioned it in the results, but gave no actual results data.

Blood lipids

Triglycerides were reported in five studies (Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Wing 1988b). Five studies reported both total cholesterol and high density lipoprotein cholesterol (Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Wing 1988b). Three of these studies also reported low density lipoprotein cholesterol (Maiorana 2002; Mourier 1997; Ronnema 1986). One study (Yeater 1990) also studied blood lipids, but did not report data in the results.

Blood pressure

Four studies provided data on blood pressure, three recording both systolic and diastolic pressure (Dunstan 1998; Dunstan 2002; Wing 1988b) and one recording only the systolic pressure (Loimaala 2003). One study measured systolic blood pressure, but only gave results for the exercise group (Yeater 1990).

Quality of life

Quality of life was measured in one study (Tessier 2000).

Fitness

Four studies addressed fitness levels (Loimaala 2003; Mourier 1997; Ronnema 1986; Yeater 1990). Yeater 1990 did not provide data for the control group.

Diabetic complications

No study included diabetic complications as an outcome.

Mortality

No study included mortality as an outcome, the intervention periods being too short.

METHODOLOGICAL QUALITY

Blinding of the people administering the intervention and of the participants actually performing the exercise is not possible in exercise intervention trials, so, as stated in the methods, blinding of these was not assessed as a quality criterion. However, blinding of the outcome assessors is feasible. The methodological characteristics of the included studies are summarised in Table 02 in the Additional Tables.

Similarity at baseline

All studies included in the review reported no significant differences in the main characteristics of the participants at baseline, except for Yeater 1990, who found plasma triglyceride levels to be higher in the exercise group at baseline ($P < 0.05$).

Randomisation and allocation concealment

All selected trials were described as randomised, however, only one study reported the method of randomisation (Dela 2004), by drawing lots. No study reported allocation concealment.

Descriptions of losses to follow-up

Most studies accounted for all the randomised participants. One study did not report the number randomised, only the number analysed (Cuff 2003). One study reported that ten of the original 36 participants were 'excluded from the analysis' for a 'variety of reasons' (Tsujiuchi 2002).

Blinding of outcome assessment

No trial reported blinding of the outcome assessors.

Adequacy of length of follow-up

The longest intervention lasted 12 months (Loimaala 2003). Two studies reported 12 month post-intervention follow-ups (Raz 1994; Wing 1988b). One study (which had a 12 week intervention) had a post-intervention follow-up (which occurred at 12 months after the end of the intervention) (Raz 1994).

RESULTS

Primary outcomes

Glycaemic control

Glycated haemoglobin was reduced by 0.6% HbA_{1c} with exercise (-0.6% HbA_{1c} WMD, 95% confidence interval (CI) -0.9 to -0.3). This is both clinically and statistically significant ($P < 0.0001$) (Baldi 2003; Cuff 2003; Dela 2004; Dunstan 1998; Dunstan 2002; Loimaala 2003; Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Tessier 2000; Tsujiuchi 2002; Wing 1988b). Studying sub-group analyses, the glycated haemoglobin decrease was more pronounced in shorter studies. For studies less than three months, the decrease was -0.8% (-0.8% HbA_{1c} WMD 95% CI -1.2 to -0.4) ($P < 0.05$) (Baldi 2003; Dunstan 1998; Maiorana 2002; Mourier 1997; Raz 1994; Wing 1988b). For all studies less than six months, it was -0.7% (-0.7% HbA_{1c} WMD, 95%

CI -1.0 to -0.4) ($P < 0.05$) (Baldi 2003; Cuff 2003; Dela 2004; Dunstan 1998; Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Tessier 2000; Tsujiuchi 2002; Wing 1988b). The Yeater 1990 study reported, without providing data, that glycated haemoglobin decreased in seven of the eight participants in the exercise group, and in only two of the eight participants in the control group.

The one study including a follow-up, at 12 months post-intervention, of the original randomised groups (Raz 1994), reported that the exercise group maintained the improvement in glycated haemoglobin. The results they reported for this were: exercise intervention group ($n = 12$): 12.5 % (± 2.9) at baseline versus 10.9 % (± 2.7) at post-intervention, ($P < 0.03$); control group ($n = 16$): 12.4 % (± 4.0) at baseline to 13.1% (± 2.9) at post-intervention. Eight participants from the exercise group and four from the control group in this study were lost to follow up.

There was no significant difference in fasting plasma glucose concentrations (-0.45 mmol/L WMD, 95% CI -1.09 to 0.18) between the exercise intervention and control groups in the pooled estimate from nine studies reporting fasting plasma glucose concentration (Baldi 2003; Dela 2004; Dunstan 1998; Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Tessier 2000; Wing 1988b). The single study reporting glycaemia area under the curve (Tessier 2000), found no significant differences between the two groups (-0.60 AUC, 95% CI -2.52 to 1.32). While data were not supplied, the Yeater 1990 study also reported no significant difference in fasting plasma glucose concentrations between the two groups.

Body mass indices

In the 10 studies reporting body mass, there was no significant difference in either body mass or body mass index (Baldi 2003; Cuff 2003; Dela 2004; Dunstan 1998; Dunstan 2002; Maiorana 2002; Mourier 1997; Ronnema 1986; Tessier 2000; Wing 1988b) between the exercise intervention and control groups (0.0 kg WMD, 95% CI -3.8 to 3.8). The study Yeater 1990, which supplied no results data, also reported no change in body mass between the two groups.

However, there was a significant decrease in visceral adipose tissue reported in two studies (Cuff 2003; Mourier 1997). In these two studies, with 40 participants, visceral adipose tissue was significantly reduced in the exercise intervention compared to the control group (-45.5 cm² WMD, 95% CI -63.8 to -27.3). Each of these two studies also showed a significant decrease in subcutaneous adipose tissue in the intervention group compared to the control group, but as there was some statistical heterogeneity ($I^2 = 53.9\%$) in the meta-analysis, we have reported the results separately (Cuff 2003: -119.8 cm², 95% CI -154.8 to -84.8 ($P < 0.05$); Mourier 1997: -73.6 cm², 95% CI -124.2 to -23.0) ($P < 0.05$). The heterogeneity may be due to the fact that the Cuff 2003 intervention was 16 weeks, while the Mourier 1997 intervention was only half that (eight weeks), with a corresponding smaller decrease in subcutaneous adipose tissue.

There was a significant increase in fat free mass reported in the exercise intervention group in one study of 18 participants (Baldi 2003): 6.3 kg, 95% CI 0.0 to 12.6 ($P < 0.05$). This study also reported that there was no significant difference in overall fat mass (-3.3 kg, 95% CI -17.4 to 10.8) ($P < 0.05$).

Adverse effects

No study included adverse events as an outcome. However, some reported on the lack of serious adverse effects or exercise induced injuries in the intervention group. Baldi 2003 reported that there were no complaints or injuries after some expected muscle soreness in the early stages. Yeater 1990 reported an absence of orthopaedic complaints or injuries. Dunstan 2002 mentioned that other than transient musculoskeletal soreness, there were no major complications or injuries from exercise. Loimaala 2003 made no mention of any adverse effects, only noting that all participants successfully completed the 12 month intervention, except for one who withdrew from the study due to lack of time for training. Maiorana 2002 reported that there were no adverse events. Mourier 1997 reported that the participants' compliance and tolerance for the training regime were good and that no exercise bout was stopped for medical reasons. The other studies (Cuff 2003; Dela 2004; Raz 1994; Ronnema 1986; Tessier 2000; Tsujiuchi 2002; Wing 1988b) made no reference to any adverse effects in the exercise group.

However, Raz 1994 mentioned that one participant in the control (non-exercise) group had a cerebrovascular accident during the trial period and was withdrawn from the study.

Secondary outcomes

Insulin sensitivity

Only one study (Tessier 2000) involving 39 participants, reported insulin sensitivity, measuring the area under the insulin curve in a three hour oral glucose tolerance test, which represents insulin release over time. This study reported a significant increase in insulin sensitivity (131 AUC, 95% CI 20 to 242) ($P < 0.05$) in the exercise intervention group compared to the control group.

In other measures associated with insulin sensitivity, the Kitt constant (a constant involved in the insulin glucose tolerance test) was reported in one study of 21 participants (Mourier 1997). This constant was found to be significantly higher in the exercise intervention group than in the control group (1.5, 95% CI 0.7 to 2.3) ($P < 0.05$). In the seven studies reporting fasting plasma insulin concentrations, no significant difference was evident (-0.7 pmol/litre WMD, 95% CI -4.1 to 2.7) (Baldi 2003; Dela 2004; Dunstan 1998; Mourier 1997; Ronnema 1986; Tessier 2000; Wing 1988b). Yeater 1990 also reported that there was no significant difference in fasting plasma insulin concentration between the two groups, however data were not provided.

Blood lipids

Serum triglyceride levels were reported in six studies (Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Wing 1988b;

Yeater 1990) and the pooled data of the five studies reporting complete data showed a significant lowering of plasma triglycerides in the exercise intervention group compared with the controls (-0.25 WMD, 95% CI -0.48 to -0.02) ($P < 0.05$). The Yeater 1990 study also reported that total triglycerides decreased significantly in the exercise group, but not in the control group, however did not provide data for the control group, so this result was not included in the meta-analysis. Yeater 1990 also reported that the per cent change in triglycerides was related to training intensity ($r = 0.91$, $P < 0.01$).

In the pooled data from the five studies recording both total cholesterol and high density lipoprotein cholesterol (Maiorana 2002; Mourier 1997; Raz 1994; Ronnema 1986; Wing 1988b), there was no significant difference between the exercise group and the control group in either total cholesterol (-0.1 mmol/L WMD, 95% CI -0.4 to 0.2) or high density lipoprotein cholesterol (0.0 mmol/L WMD, 95% CI -0.1 to 0.1). In the three of these studies also reporting low density lipoprotein cholesterol (Maiorana 2002; Mourier 1997; Ronnema 1986), there were no significant differences between the two groups (0.1 mmol/L WMD, 95% CI -0.3 to 0.5). These results were also confirmed by the Yeater 1990 trial which, while not providing data, reported no difference between the exercise and control groups in total cholesterol, high density lipoprotein cholesterol or low density lipoprotein cholesterol.

Blood pressure

The change in systolic blood pressure, reported in four studies (Dunstan 1998; Dunstan 2002; Loimaala 2003; Wing 1988b), was -4 mmHg WMD, 95% CI -10 to +1. There was no significant difference between exercise intervention and control groups. The other study which measured systolic blood pressure (Yeater 1990) only gave results for the exercise group, reporting that resting systolic blood pressure decreased significantly from 141 to 130 mmHg in this group.

The change in diastolic blood pressure, reported in three studies (Dunstan 1998; Dunstan 2002; Wing 1988b), was 0 mmHg WMD, 95% CI -4 to +3. There was no significant difference between exercise intervention and control groups.

Quality of life

There was no significant change in the quality of life assessment with exercise in the one study reporting this outcome (Tessier 2000), with no significant difference between exercise intervention and control groups.

Fitness levels

Three studies (95 participants) reported complete data for fitness as measured by maximal oxygen uptake (VO_{2max}) (Loimaala 2003; Mourier 1997; Ronnema 1986). However, there was significant heterogeneity when all three were combined in a meta-analysis ($I^2 = 75.8$). Thus, the combined result is only reported for two trials (Loimaala 2003; Ronnema 1986), for which there was no heterogeneity ($I^2 = 0\%$). The combined result (2 ml/kg*min WMD, 95% CI 0 to 5) was not significant ($P < 0.09$). On the

other hand, the Mourier 1997 study reported that fitness improved significantly (9 % VO_{2max} , 95% CI 6 to 13) ($P < 0.05$). This was supported by a further study (Yeater 1990), however as no data were provided for the control group in this study, the results could not be included in the meta-analysis.

Diabetic complications

No hypoglycaemic reactions or development of diabetic complications were reported in any of the trials in the exercise group. The Dunstan 2002 study explicitly reported that there were no major complications in the exercise group. Mourier 1997 reported that participants had good tolerance for the training regime and that no exercise bout was stopped for medical reasons. Raz 1994 mentioned that one participant in the control group had a cerebrovascular accident and was withdrawn from the study. The other trials made no mention of any diabetic or other complications.

Mortality

No trial assessed mortality as a primary or secondary outcome.

Heterogeneity

Of the outcomes tested, there was only substantial heterogeneity in the results of trials for the outcomes of subcutaneous adipose tissue and maximal exercise capacity. In the case of the two studies reporting subcutaneous adipose tissue (Cuff 2003; Mourier 1997), the I^2 statistic for heterogeneity was 53.9%, so the results show some heterogeneity. The heterogeneity may be due to the fact that the Cuff 2003 trial length was 16 weeks, while the Mourier 1997 trial length was only half that (eight weeks), resulting in a smaller decrease in subcutaneous adipose tissue.

Complete data for maximal exercise capacity ($I^2 = 75.8\%$), were reported in three studies (Loimaala 2003; Mourier 1997; Ronnema 1986). If Mourier 1997 is deselected in the meta-analysis, heterogeneity is no longer apparent between Loimaala 2003 and Ronnema 1986. The different protocols employed, different exercise equipment used and diversity in the initial fitness status of the participants in the studies may explain the heterogeneity.

Subgroup analyses

Length of the intervention subgroup analyses were performed for glycated haemoglobin. Including only the six studies with a less than three month intervention (158 participants) that provided sufficient data, the drop in glycated haemoglobin was significant (-0.8% WMD, 95% CI -1.2 to -0.4) with $I^2 = 0\%$ (Baldi 2003; Dunstan 1998; Maiorana 2002; Mourier 1997; Raz 1994; Wing 1988b). When studies of less than three months duration were excluded, the decrease in glycated haemoglobin was significant for the remaining seven studies (203 participants) (-0.5% WMD, 95% CI -0.8 to -0.1) with $I^2 = 0\%$ (Cuff 2003; Dela 2004; Dunstan 2002; Loimaala 2003; Ronnema 1986; Tessier 2000; Tsujiuchi 2002). Excluding the longest study (Loimaala 2003; 12 months duration) had no significant effect on the percentage glycated haemoglobin result (-0.6% HbA1c WMD, 95% CI -0.9 to -0.3) with $I^2 = 0\%$. After excluding the two longest studies (six months Dunstan 2002; 12 months Loimaala 2003), the drop in

glycated haemoglobin remained significant (-0.7% WMD, 95% CI -1.0 to -0.4, $I^2 = 0\%$). Hence based on subgroup analysis, the decrease in glycated haemoglobin in shorter studies (less than three months: -0.8%; and less than 6 months: -0.7%) was more pronounced than the decrease for all the studies combined (-0.6%).

Sensitivity analyses

Not performed due to lack of relevant data.

Assessment of publication bias

Funnel plots for the main outcomes, glycated haemoglobin and body mass, were visually assessed as reasonably symmetrical, indicating little publication or small study bias.

Follow-up

The Raz 1994 study provided follow-up glycated haemoglobin data on the randomised groups, 12 months after the end of the 12 week exercise intervention for 12 of the 20 exercise intervention participants and 16 of the 20 participants in the control group. This trial showed that the exercise intervention group maintained a significant improvement in glycated haemoglobin levels, while the control group did not: Exercise intervention group: $10.9 \pm 2.7\%$ HbA_{1c} at 12 months post-intervention versus $12.5 \pm 2.9\%$ HbA_{1c} at baseline, $P < 0.03$; control group: $13.1 \pm 2.9\%$ HbA_{1c} at 12 months post-intervention versus $12.4 \pm 4.0\%$ HbA_{1c} at baseline. The Wing 1988b study also had a 12 month post-intervention follow-up and reported that at one year, the medication for participants in the exercise intervention group was reduced by 83%, while medication for participants in the control group was reduced by only 38%.

DISCUSSION

Summary

An exercise intervention resulted in a clinically significantly improvement in glycaemic control compared to controls. The decrease of 0.6% HbA_{1c} (13 trials) was achieved over relatively short periods of time, since the shortest studies in the review were of eight weeks duration (Dunstan 1998; Maiorana 2002; Mourier 1997) and there were only two studies with an intervention of six months or more (Dunstan 2002) (six months) and (Loimaala 2003) (twelve months). Analysis of sub-groups showed a trend to the shorter trials producing a slightly more pronounced improvement in glycaemic control (-0.8% HbA_{1c} for studies of three months or less and -0.7% HbA_{1c} for all studies less than six months), compared to -0.6% HbA_{1c} for all thirteen trials. This probably reflects both the higher intensity of the exercise in some of the shorter trials, as well as the difficulties of maintaining compliance with exercise regimes in longer term studies. Results from the fourteenth study (Yeater 1990) also support the fact that exercise improved glycaemic control. Yeater 1990 reported improved glycaemic control in seven of the eight participants in the exercise group, compared to only two out of eight participants in the controls.

There is some evidence that the improvement in glycaemic control can be maintained in the longer term. In the 12 month post-intervention follow-up reported by Raz 1994, the participants continuing to exercise maintained the improvement in glycaemic control, while the others had not. However, there were large losses to follow-up. In the only other study that reported a 12 month post-intervention follow-up (Wing 1988b), they found that medication for participants in the exercise intervention group was more greatly reduced, than for those in the control group. However for this study also, there were losses to follow-up.

It is generally difficult to motivate people to exercise. A gradual increase in exercise, starting from low intensity and increasing to moderate exercise performed regularly may be a more successful approach to incorporate exercise into daily lives on a long term basis, than introducing more intense levels of exercise at the outset, which will be difficult to maintain in the longer term. The Yeater 1990 study attributed the high rate of compliance in their study partly to the initial low intensity and gradual progression of the exercise, which was individualised for each person. The exercise intervention in this study, which started at low intensity walking and gradually increased to moderate walking or gentle jogging resulted in significantly improved glycaemic control and fitness, and decreased resting systolic blood pressure and fasting triglycerides.

The mean reduction of 0.6% HbA_{1c} achieved compares well with reported reductions achieved through medications. Meta-analysis has shown that metformin can lower glycated haemoglobin levels by 0.9% (-0.9% HbA_{1c} WMD, 95% CI -1.1 to -0.7) compared to placebo, and sulphonylureas have been shown to have a similar effect (Campbell 1995; Johansen 1999).

The clinical significance of a 0.6% decrease in glycated haemoglobin can be gauged by studying the large prospective intervention studies examining morbidity and mortality outcomes in people with type 2 diabetes. An epidemiological interpretation of the United Kingdom Prospective Diabetes Study Group data suggests that a 1% rise in glycated haemoglobin represents a 21% increase in risk for any diabetes-related endpoint (95% CI 17 to 24, $P < 0.0001$), a 21% increase in risk for any diabetes-related death (95% CI 15 to 27, $P < 0.0001$), a 14% increased risk for myocardial infarction (95% CI 8 to 21, $P < 0.0001$) and a 37% increased risk for microvascular complications (95% CI 33 to 41, $P < 0.0001$) (Stratton 2000). The group found that there was no threshold value of glycated haemoglobin for any adverse outcome and concluded that any reduction in glycated haemoglobin was likely to reduce the risk of complications, with the lowest risk being in those with normal glycated haemoglobin levels (less than 6%).

The impact of a decrease of 0.6% HbA_{1c} equates to a 30% improvement towards a target value of 7% HbA_{1c}, and a 20% improvement towards a normal value of 6% HbA_{1c}, for a person diagnosed with 9% HbA_{1c}. Hence, possible improvements achievable through exercise are not insubstantial.

Improvements in glycaemic control were achieved over a range of exercise intensities. For example, improvements in glycated haemoglobin were observed following low intensity exercise such as a one hour weekly session of Qi Gong (Tsujuchi 2002), moderate intensity exercise such as walking three times per week at 60 to 79% of maximal oxygen uptake (Tessier 2000) and high intensity exercise regimes that included progressive resistance training of three sets of ten to twelve repetitions of lifting weights that represented 70 to 85% of a maximum voluntary contraction load of a muscle group (Loimaala 2003).

In addition to the decrease in glycated haemoglobin, there was also a significant decrease in fat mass and in visceral adipose tissue, thus exercise is contributing to decreasing one of the major risk factors for the metabolic syndrome. Despite the decrease in fat, there was no decrease in body mass and this probably reflects a significant increase in fat free mass or muscle mass. Participants in the exercise group are likely to have developed muscle, which is heavier than adipose tissue. In the early stages of an exercise programme, an increase in muscle mass would obscure any weight loss due to adipose tissue loss. Over time muscle mass does not keep increasing to the same extent as adipose tissue loss and eventually weight loss occurs due to loss of adipose tissue. The length of most of the included trials was too short to show change in body mass. Interventions for sustained weight change require durations of up to one year.

There was also a significant lowering of plasma triglycerides in the exercise intervention group compared with the controls, but there was no significant difference between groups in either total cholesterol or blood pressure. However, one study, not included in the meta-analysis (Yeater 1990), did report a significant decrease in systolic blood pressure with exercise.

In the one study reporting insulin response, there was increased insulin sensitivity in the exercise intervention group, which would contribute to improved glycaemic control. However, it was observed in another study that no benefits could be expected in patients who already had poor metabolic control and weak insulin reserves (Ronnemaa 1986).

Quality of life did not decrease when exercise sessions were included as reported in the study addressing quality of life (Tessier 2000).

There were no serious adverse effects reported as a result of any of the exercise interventions and no hypoglycaemic reactions or development of diabetic complications were reported in any of the trials in the exercise group. No trial aimed to observe mortality, due to the restricted study periods.

These results show a need to be process (engagement) rather than product (weight loss) focussed. In several studies, despite the lack of weight loss, good compliance and programme design resulted in lifestyle, biochemical, biological and other systemic benefits in people with type 2 diabetes. Feedback to people about these other

important health outcomes may improve exercise adherence and hence the sustainability of the intervention. Variety, with a choice of the exercise activity, may also be important to ensure compliance with exercise programmes beyond the period of the intervention.

Limitations of the review

Most studies included in this review were well-designed, even though there are some methodological limitations, some of which may be due to reporting standards prevalent in the year in which the study was performed. While all the included studies were reported as randomised, few reported the method of randomisation, or allocation concealment. However, in some of these studies, the same participants took part in both the intervention and control arms of the study. No study reported blinding of outcome assessors. Analyses for the results were not always performed on an intention-to-treat basis, however most studies reported on the reasons why people had dropped out of the study.

The length of trials prevented the reporting of any significant long term complications or mortality. Another limitation of the review was the small number of participants included in the analyses for visceral and subcutaneous adiposity, blood pressure, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, fat free mass and quality of life.

Exercise prescriptions are difficult for many people to maintain over the longer term. The longest study in this review was 12 months (Loimaala 2003), with one study (Raz 1994) having a one year post-intervention follow-up and another study (Wing 1988b) reporting a one year general post-intervention follow-up, but not comparing the participants according to their original randomised groups. It is possible that the length of the trials included in the review was not sufficient to result in any loss in total body mass, even though a decrease in visceral adipose tissue was reported. Longer term trials are needed to evaluate whether long term exercise maintains the improved glycaemic control. Inclusion of regular exercise into daily routines requires a lifestyle change that could be justified, if long term trials demonstrated compliance and longer term benefits such as decreased rates of diabetic complications.

Generalisability and applicability of the results

We identified fourteen randomised controlled trials (377 participants) which assessed exercise against no exercise in people with type 2 diabetes. These studies involved either aerobic or resistance training exercise interventions or a combination of both of these. The studies were conducted in nine different countries. Participants included both male and female adults of mean age over 45 years, hence the results particularly apply to the age group at most risk for type 2 diabetes.

AUTHORS' CONCLUSIONS

Implications for practice

This systematic review found that exercise per se significantly decreased glycated haemoglobin levels (by 0.6% HbA_{1c}), and hence improved glycaemic control in people with type 2 diabetes mellitus to a clinically significant degree. For a person diagnosed with a glycated haemoglobin value of 9% HbA_{1c}, this represents a 30% improvement towards a target glycated haemoglobin value of 7% HbA_{1c}, and a 20% improvement towards a normal value of 6% HbA_{1c}. Hence, possible improvements achievable through exercise are not insubstantial.

Thus, exercise can be recommended in the management of type 2 diabetes, and can lead to amelioration of the diabetes. This can benefit the patient, by either lessening or even avoiding the requirement for medication. Adverse effects were neither stated as outcomes, nor reported for the intervention group, in any of the studies.

The significant improvement in glycaemic control, increase in insulin sensitivity and increase in fat free mass, and decrease in visceral adipose tissue, even though overall body mass did not decrease, is good feedback with a patient focus to enable discussion of benefits not necessarily seen on body weight scales.

Because the included studies had interventions involving different types of exercise, the most suitable type of exercise can be individually determined for a person, so as provide an acceptable low cost, convenient mode of activity. The easier the exercise is to maintain, the more likely it is that people will do it. Therefore, mild to moderate exercise performed regularly will be of more benefit, than short bursts of high intensity exercise, which would be difficult to maintain over long periods.

Dedicated exercise regimes should be prescribed in addition to lifestyle-based incidental types of activities for everyday life, such as cycling rather than using the car. Other examples of these incidental activities are taking the stairs rather than the lift, using facilities on different levels in multi-storey buildings, parking the car further away and carrying groceries rather than pushing them in a cart. A baseline sedentary population appears likely to gain health benefits from multiple opportunities to increase energy expenditure.

Interventions in which the exercise prescription involved a variety of activities were as effective as those interventions using a single mode of exercise. A variety of exercise types may thus be the key to making exercise more acceptable to people, increasing the sustainability of the exercise so as to obtain longer term health benefits. Programmes using a single mode of exercise may become too monotonous over long periods of time.

Implications for research

As there is some evidence that the improvement in glycaemic control can be maintained in the longer term, further studies with longer exercise interventions and with post-intervention follow-ups of at least six to twelve months are required to assess whether exercise prescriptions can be maintained as part of a regular lifestyle. Long term intervention studies would be useful to determine whether the participants can continue with the exercise prescription and also whether the decrease in glycated haemoglobin and consequent improved glycaemic control is maintained over longer periods, as well as whether body mass eventually decreases.

Variables that appear to be under-explored are exercise-related improvements in primary outcomes with a strong patient focus, including quality of life, attitudes to diabetes and overall cardiorespiratory health. With the increasing trend towards type 2 diabetes appearing at younger ages, even during childhood, there is a need for studies in these younger age groups. There is also a further need for studies with enough power and duration to detect effects for outcomes such as long term complications of diabetes.

POTENTIAL CONFLICT OF INTEREST

None known.

ACKNOWLEDGEMENTS

We acknowledge expert diabetes advice from Associate Professor C Cowell, Head, Department of Endocrinology, The Children's Hospital at Westmead; contribution to the protocol by Mr. N Boule, Dr E Haddad, Dr G Kenny, Dr G Wells and Dr R Sigal, and thank Professor Y Sato, Dr C Bogardus and Dr P Boudou for responding to our queries. Dr Boudou kindly confirmed our deduction that both Boudou 2001 and Mourier 1997 belong to the same study, hence these two papers have been grouped together under Mourier 1997.

SOURCES OF SUPPORT

External sources of support

- Nutricia AUSTRALIA
- Financial Markets Foundation for Children AUSTRALIA

Internal sources of support

- The Children's Hospital at Westmead, NSW AUSTRALIA
- The University of Sydney AUSTRALIA

REFERENCES

References to studies included in this review

- Baldi 2003** {published data only}
Baldi JC, Snowling N. Resistance training improves glycaemic control in obese type 2 diabetic men. *International Journal of Sports Medicine* 2003;**24** (6):419–23.
- Cuff 2003** {published data only}
Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective Exercise Modality to Reduce Insulin Resistance in Women With Type 2 Diabetes. *Diabetes Care* 2003;**26** (11):2977–82.
- Dela 2004** {published data only}
Dela F, von Linstow ME, Mikines KJ, Galbo H. Physical training may enhance beta-cell function in type 2 diabetes. *American Journal of Physiological and Endocrinological Metabolism* 2004;**287** (5):E1024–31.
- Dunstan 1998** {published data only}
Dunstan DW, Puddey IB, Beilin LJ, Burke V, Morton AR, Stanton KG. Effects of a short-term circuit weight training program on glycaemic control in NIDDM. *Diabetes Research and Clinical Practice* 1998;**40**:53–61.
- Dunstan 2002** {published data only}
Dunstan DW, Daly RM, Owen N, Jolley D, Court D, Shaw J, Zimmet P. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. *Diabetes Care* 2002;**25** (10):1729–36.
- Loimaala 2003** {published data only}
Loimaala A, Huikuri HV, Koobi T, Rinne M, Nenonen A, Vuori I. Exercise training improves baroreflex sensitivity in type 2 diabetes. *Diabetes* 2003;**52** (7):1837–42.
- Maiorana 2002** {published data only}
Maiorana A, O'Driscoll G, Goodman C, Taylor R, Green D. Combined aerobic and resistance exercise improves glycemic control and fitness in type 2 diabetes. *Diabetes Research & Clinical Practice* 2002;**56**(2):115–23.
- Mourier 1997** {published data only}
Boudou P, de Kerviler E, Erlich D, Vexiau P, Gautier JF. Exercise training-induced triglyceride lowering negatively correlates with DHEA levels in men with type 2 diabetes. *International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity* 2001;**25**(8):1108–12.

* Mourier A, Gautier J-F, De Kerviler E, Bigard AX, Villette J-M, et al. Mobilization of Visceral Adipose Tissue Related to the Improvement in Insulin Sensitivity in Response to Physical Training in NIDDM. *Diabetes Care* 1997;**20**(3):385–91.
- Raz 1994** {published data only}
Raz I, Hauser E, Bursztyjn M. Moderate exercise improves glucose metabolism in uncontrolled elderly patients with non-insulin-dependent diabetes mellitus. *Israeli Journal of Medical Science* 1994;**30**:766–70.
- Ronnemaa 1986** {published data only}
Ronnemaa T, Marniemi J, Puukka P, Kuusi T. Effects of long-term physical exercise on serum lipids, lipoproteins and lipid metabolizing enzymes in type 2 (non-insulin-dependent) diabetic patients. *Diabetes Research* 1988;**7**:79–84.

* Ronnema T, Mattila K, Lehtonen A, Kallio V. A controlled randomized study on the effect of long-term physical exercise on the metabolic control in type 2 diabetic patients. *Acta Medica Scandinavica* 1986;**220**:219–24.
- Tessier 2000** {published data only}
Tessier D, Menard J, Fulop T, Ardilouze J, Roy M, Dubuc N, et al. Effects of aerobic physical exercise in the elderly with type 2 diabetes mellitus. *Archives of Gerontology & Geriatrics* 2000;**31**(2):121–32.
- Tsujiuchi 2002** {published data only}
Tsujiuchi T, Kumano H, Yoshiuchi K, He D, Tsujiuchi Y, Kuboki T, et al. The effect of Qi-gong relaxation exercise on the control of type 2 diabetes mellitus: a randomized controlled trial. *Diabetes Care* 2002;**25**(1):241–2.
- Wing 1988b** {published data only}
Wing RR, Epstein LH, Paternostro-Bayles M, Kristka A, Nowalk MP, Gooding W. Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes. *Diabetologia* 1988;**31**:902–9.
- Yeater 1990** {published data only}
Yeater R A, Ullrich IH, Maxwell L P, Goetsch V I. Coronary risk factors in type II diabetes: response to low-intensity aerobic exercise. *West Virginia Medical Journal* 1990;**86**(7):287–90.

References to studies excluded from this review

- Agurs-Collins 1997**
Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL. A randomized controlled trial of weight reduction and exercise for diabetes management in older african-american subjects. *Diabetes Care* 1997;**20**(10):1503–11.
- Biermann 1986**
Biermann J. Modification of disordered glucose metabolism by physical training of low intensity. *Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete* 1-7-1986;**41**(13):375–7.
- Blonk 1994**
Blonk MC, Jacobs MAJM, Biesheuvel EHE, Weeda-Mannak WL, Heine RJ. Influences on weight loss in type 2 diabetic patients: Little long-term benefit from group behaviour therapy and exercise training. *Diabetic Medicine* 1994;**11**:449–57.
- Bogardus 1984**
Bogardus C, Ravussin E, Robbins DC, Wolfe RR, Horton ES, Sims EA. Effects of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. *Diabetes* 1984;**33**(4):311–8.
- Dunstan 1997**
Dunstan DW, Mori TA, Puddey IB, Beilin LJ, Burke V, Morton AR, et al. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics. *Thrombosis & Haemostasis* 1999;**81**(3):367–72.

* Dunstan DW, Mori TA, Puddey IB, Beilin LJ, Burke V, Morton AR, et al. The independent and combined effects of aerobic exercise and

- dietary fish intake on serum lipids and glycemic control in NIDDM. *Diabetes Care* 1997;**20**(6):913–21.
- Ferrier 2004**
Ferrier KE, Nestel P, Taylor A, Drew BG, Kingwell BA. Diet but not aerobic exercise training reduces skeletal muscle TNF-alpha in overweight humans. *Diabetologia* 2004;**47**(4):630–7.
- Fujii 1982**
Fujii S, Okuno Y, Okada K, Tanaka S, Seki J, Wada M, et al. Effects of physical training on glucose tolerance and insulin response in diabetics. *Osaka City Medical Journal* 1982;**28**:1–8.
- Honkola 1997**
Honkola A, Forsen T, Eriksson J. Resistance training improves the metabolic profile in individuals with type 2 diabetes. *Acta Diabetologica* 1997;**34**:245–8.
- Ishii 1998**
Ishii T, Yamakita T, Sato T, Tanaka S, Fujii S. Resistance training improves insulin sensitivity in niddm subjects without altering maximal oxygen uptake. *Diabetes Care* 1988;**21**(8):1353–5.
- Kaplan 1985**
Kaplan RM, Wilson DK, Hartwell SL, Merino KL, Wallace JP. Prospective evaluation of HDL cholesterol change after diet and physical conditioning programs for patients with type II Diabetes Mellitus. *Diabetes Care* 1985;**8**(4):343–8.
- Kaplan 1987**
Kaplan RM, Hartwell SL, Wilson DK, Wallace JP. Effects of diet and exercise interventions on control and quality of life in non-insulin-dependent diabetes mellitus. *Journal of General Internal Medicine* 1987;**2**:220–7.
- Khan 1995**
Khan S, Rupp J. The effect of exercise conditioning, diet, and drug therapy on glycosylated hemoglobin levels in type 2 (NIDDM) diabetics. *The Journal of Sports Medicine and Physical Fitness* 1995;**35**:281–8.
- Lehmann 1995**
Lehmann R, Vokac A, Niedermann K, Agosti K, Spinass GA. Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. *Diabetologia* 1995;**38**:1313–9.
- Ligtenberg 1997**
Ligtenberg PC, Hoekstra JBL, Bol E, Zonderland ML, Erkelens DW. Effects of physical training on metabolic control in elderly type 2 diabetes mellitus patients. *Clinical Science* 1997;**93**:127–35.
- Samaras 1997**
Samaras K, Ashwell S, Mackintosh AM, Fleury AC, Campbell LV, Chisholm DJ. Will older sedentary people with non-insulin-dependent diabetes mellitus start exercising? A health promotion model. *Diabetes Research & Clinical Practice* 1997;**37**(2):121–8.
- Skarfors 1987**
Skarfors ET, Wegerner TA, Lithell H, Selinus I. Physical training as treatment for type 2 (non-insulin-dependent) diabetes in elderly men. A feasibility study over 2 years. *Diabetologia* 1987;**30**:930–3.
- Vanninen 1992**
Vanninen E, Uusitupa M, Siitonen O, Laitinen J, Lansimies E. Habitual physical activity, aerobic capacity and metabolic control in patients with newly-diagnosed Type 2 (non-insulin-dependent) diabetes mellitus: Effect of 1-year diet and exercise intervention. *Diabetologia* 1992;**35**:340–6.
- Verity 1989**
Verity LS, Ismail AH. Effects of exercise on cardiovascular disease risk in women with NIDDM. *Diabetes Research & Clinical Practice* 1989;**6**(1):27–35.
- Wing 1988a**
Wing RR, Epstein LH, Paternostro-Bayles M, Kristka A, Nowalk MP, Gooding W. Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes. *Diabetologia* 1988;**31**:902–9.
- Yamanouchi 1995**
Yamanouchi K, Shinozaki T, Chikada K, Nishikawa T, Ito K, Shimizu S, et al. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. *Diabetes Care* 1995;**18**(6):775–8.

Additional references

ADA 1997

American Diabetes Association. Diabetes mellitus and exercise. *Diabetes Care* 1997;**20**(12):1908–12.

ADA 1997b

American Diabetes Association. Report on the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997;**20**:1183–97.

Albright 2005

Albright A, Franz M, Hornsby G, Kriska A, Marrero D, et al. American College of Sports Medicine Position Stand: Exercise and Type 2 Diabetes. *Medicine and Science in Sports and Exercise* 2005:1345–60.

Bouchard 1994

Bouchard C, Shephard RJ, Stephens TE. *Physical activity, fitness, and health: international proceedings and consensus statement*. Champaign, Ill, Human Kinetics Publishers, 1994.

Boule 2001

Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *Journal of the American Medical Association* 2001 September;**286**(10):1218–27.

Brown 1996

Brown SA, Upchurch S, Anding R, Winter M, Ramirez G. Promoting weight loss in type II diabetes. *Diabetes Care* 1996;**19**(6):613–24.

Campbell 1995

Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. *Diabetes Metabolism Reviews* 1995;**11** Suppl 1:S57–S62.

Constantini 2005

Constantini N, Harman-Boehm I, Dubnov G. Exercise prescription for diabetics: more than a general recommendation. *Harefuah* 2005;**144**(10):717–23, 750.

Cooper 1994

Cooper H, Hedges LV. *The handbook of research synthesis*. New York: Russell Safe Foundation, 1994.

- Després 1997**
Després JP. Visceral obesity, insulin resistance, and dyslipidemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome. *Exercise and Sport Science Reviews* 1997; **25**:271–300.
- Fleiss 1981**
Fleiss. *Statistical Methods for Rates and Proportions*. 2nd Edition. New York: Wiley, 1981:217–34.
- Higgins 2003**
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**:557–560.
- Ivy 1997**
Ivy JL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. *Sports Medicine* 1997; **24**(5):321–36.
- Jadad 1996**
Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gaghagh DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. *Controlled Clinical Trials* 1996; **17**:1–12.
- Johansen 1999**
K. Johansen. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. *Diabetes Care* 1999; **22**(1):33–7.
- Joslin 1959**
Joslin EP, Root EF, White P. *The Treatment of Diabetes Mellitus*. Philadelphia: Lea & Febiger, 1959:243–300.
- Kelley 1995**
Kelley G, Tran ZV. Aerobic exercise and normotensive adults: a meta-analysis. *Medicine & Science in Sports & Exercise* 1995; **27**(10):1371–7.
- King 1995**
King DS, Baldus PJ, Sharp RL, Kesl LD, Feltmeyer TL, Riddle MS. Time course for exercise-induced alterations in insulin action and glucose tolerance in middle-aged people. *Journal of Applied Physiology* 1995; **78**(1):17–22.
- Lamarche 1998**
Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. *JAMA* 1998; **279**(24):1955–61.
- Meltzer 1998**
Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. *Canadian Medical Association Journal* 1998; **8 Suppl**:S1–S29.
- NDDG 1979**
National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 1979; **28**:1039–57.
- NIH 1998**
National Institutes of Health, National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report 1998.
- Peters 1996**
Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. *JAMA* 1996; **276**(15):1246–52.
- Schultz 1995**
Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995; **273**:408–12.
- Shaw 2001**
Shaw K, Del Mar C, O'Rourke P, Tito F. Exercise for Obesity (Protocol for a Cochrane Review). In: *The Cochrane Database of Systematic Reviews*, 1, 2004.
- Stratton 2000**
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000; **321**(7258):405–12.
- Wallberg-H. 1998**
Wallberg-Henriksson H, Rincon J, Zierath JR. Exercise in the management of non-insulin-dependent diabetes mellitus. *Sports Medicine* 1998; **25**(1):25–35.
- WHO 1980**
WHO expert committee on diabetes mellitus. World Health Organization. Technical Report Series 1980; Vol. 646:1–80.
- WHO 1999**
World Health Organization. World Health Report 1999.
- Yki-Yarvinen 1998**
Yki-Yarvinen H. Toxicity of hyperglycaemia in type 2 diabetes. *Diabetes and Metabolism Reviews* 1998; **14**:S45–S50.

* Indicates the major publication for the study

T A B L E S

Characteristics of included studies

Study	Baldi 2003
Methods	Study design: randomised controlled trial Randomisation procedure: not reported

Exercise for type 2 diabetes mellitus (Review)

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd

Characteristics of included studies (Continued)

	Allocation concealment: Not reported Blinding of outcome assessors: Unclear Length of intervention: 10 weeks Intention-to-treat analysis: Yes
Participants	Diagnosis: Non-insulin dependent diabetes mellitus (at least 3 years) male obese Setting: Community n = 18 Intervention Group: n = 9, Control group: n=9, Mean age: intervention group 45.5 +/- 6.3 years, control group 50.1 +/- 3.9 years Medications: oral hypoglycaemic agents, biguanidines n=5 in exercise group and n=1 in control group; sulfonylureas n=3 in exercise group and n=4 in control group, insulin n=0 Baseline characteristics: Reported Geographical location: New Zealand
Interventions	Intervention. Exercise Times per week: 3 supervised sessions Duration of each session: not stated Intensity: Progressive resistance training
Outcomes	Glycated haemoglobin, body mass, baseline glucose and insulin, fat free mass and fat mass
Notes	Muscle strength gains ranged from 25 to 52%.
Allocation concealment	B – Unclear

Study Cuff 2003

Methods	Study design: randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 16 weeks Intention-to-treat analysis: Yes
Participants	Diagnosis: Non-insulin dependent diabetes mellitus post menopausal women Setting: Community n = 19 Mean age: Intervention group: 63.4 +/- 7.0 years; Control group: 60.0 +/-8.7 years Medications: One oral hypoglycaemic agent exercise group n = 1, control group n= 2, more than one oral agent exercise group n= 3, control group n= 1 Baseline characteristics: Reported Geographical location: Canada
Interventions	Intervention: Exercise Times per week: 3 Duration of each session: 75 minutes Intensity: 65-75% of heart rate reserve during aerobic activities, plus resistance training
Outcomes	Glycated haemoglobin, body mass, subcutaneous adipose tissue, visceral adipose tissue
Notes	Third experimental group had aerobic training only as the intervention.
Allocation concealment	B – Unclear

Study Dela 2004

Methods	Study design: Randomised controlled trial Randomisation procedure: by drawing lots Allocation concealment: unclear Blinding of outcome assessors: Unclear Length of intervention: 3 months
---------	---

Characteristics of included studies (Continued)

	Intention-to-treat analysis: Yes
Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Community n = 16 Intervention group: n = 9 Control group: n=7 Mean Age: Intervention group: 54 +/- 6 years; control group 53 +/- 11 years Male/female: all male Other characteristics: Medications Oral hypoglycaemic agents: low insulin secreters n=8, moderate insulin secreters n=9, participants abstained from medication on exercise days Baseline characteristics: Reported Geographical location: Denmark
Interventions	Intervention Exercise. Times per week: 5 Duration of each session: 20 minutes Intensity: 75% VO2max
Outcomes	Glycated haemoglobin, fasting glucose, fasting insulin, body mass, Body Mass Index
Notes	Supervision through hidden counters and diaries used in a homebased study.
Allocation concealment	B – Unclear

Study Dunstan 1998

Methods	Study design: Randomised controlled trial Randomisation procedure: Block randomisation Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 8 weeks Intention-to-treat analysis: Not done
Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Out patients n =27 Mean age: 51 years Male/female: 17 males, 10 females Other characteristics: sedentary, untrained, with established, but controlled non-insulin dependent diabetes mellitus Medication: oral hypoglycaemic agents n=10 on both biguanidines and sulfonylureas, n=4 on sulfonylureas alone and n=5 on biguanidines alone Baseline characteristics: Reported Geographical location: Australia
Interventions	Intervention Exercise. Times per week: 3 supervised Prescribed progressive resistance training circuit weight training Intensity: 2 sets at 50-55% of 1 repetition maximum (RM), 2 sets at 50-55% 1RM first 6 sessions, then 3 sets until program completion. Re testing of 1RM at 0, 4 and 8 weeks
Outcomes	Glycated haemoglobin, weight, Waist to height ratio, Body Mass Index, fasting plasma insulin and glucose, blood pressure
Notes	
Allocation concealment	B – Unclear

Study Dunstan 2002

Methods	Study design: Randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 6 months Intention-to-treat analysis: Not done
---------	--

Characteristics of included studies (Continued)

Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Community n=36 Intervention: n=16 Mean age: 67.6+/-5.2 years Male/female: 10 male, 6 female Control Group n=13 Mean age: 66.9 +/- 5.3 years, Male/female: 6 male, 7 female Other characteristics: oral hypoglycaemic agents, exercise n =15 and control n=10 Baseline characteristics: Reported Geographical location: Australia
Interventions	Intervention. Exercise. Times per week: 3 Duration of each session: 55 minutes Intensity: Progressive resistance training. With weight loss diet Control Group: Weight loss diet alone
Outcomes	Glycated haemoglobin, blood pressure, body mass,
Notes	High compliance. 19% drop out rate, reasons given
Allocation concealment	B – Unclear

Study **Loimaala 2003**

Methods	Study design: Randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 12 months Intention-to-treat analysis: Not done
Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Community n=50 Intervention group: n=24 Control Group: n=25 Mean age: Intervention: 53.6 +/- 6.2 years; Control: 54.0 +/-5.0 years Male/female: All male Other characteristics: Medication oral hypoglycaemic agents n = 36 Baseline characteristics: Reported Geographical location: Finland.
Interventions	Intervention: Exercise Times per week: 3 supervised and 1 unsupervised per week Duration of each session: Greater than 30 minutes Intensity: 2 walking sessions at 65-75%VO ₂ max plus 2 progressive resistance training sessions of 3 sets and 10-12 repetitions at 70-80% of a maximum voluntary contraction
Outcomes	Glycated haemoglobin, systolic blood pressure, VO ₂ max, Body Mass Index
Notes	One participant left due to lack of time for training
Allocation concealment	B – Unclear

Study **Maiorana 2002**

Methods	Study design: Crossover Randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 8 weeks Intention-to-treat analysis: Yes
---------	---

Characteristics of included studies (Continued)

Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Out-patients n=16 Mean age: 52 +/- 8 yr Male/female: 14 male, 2 female Other characteristics: non-smokers, normo-tensive. Medications: ACE inhibitors 5/16, lipid lowering therapy n=2, aspirin n=2, oral hypoglycaemic drugs n=11 Baseline characteristics: Reported Geographical location: Australia
Interventions	Intervention. Exercise Times per week: 3. Duration of each session: 1 hour. Intensity: circuit of progressive resistance training (65% of 1 maximum repetition by week 4) alternated with cycling up to 85% peak heart rate for 8 weeks
Outcomes	Glycated haemoglobin, triglycerides, VO2 peak, fasting blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, arterial blood pressure, resting heart rate
Notes	Good compliance, all completed 24 exercise sessions and the exercise regimen was well tolerated
Allocation concealment	B – Unclear

Study **Mourier 1997**

Methods	Study design: Randomised controlled trial Randomisation procedure: Not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 8 weeks Intention-to-treat analysis: Not done
Participants	Diagnosis: Non-insulin dependent diabetes mellitus n = 24 (for Boudou 2001 n=16, all male) Setting: Out-patients Mean age: 45 +/-2 years Male/female: 20 male, 4 female Other characteristics: Stable weight and mean duration of diabetes 59 +/- 24 months. Good control (mean glycated haemoglobin 7.9%), Medications hypoglycaemic agents n=20, metformin n=14, sulfonylurea n =3 Baseline characteristics: Reported Geographical location: France
Interventions	Intervention: Exercise Times per week: 3 (2 continuous at 75% VO2 peak, 1 intermittent of 5 bouts at 85% VO2 peak for 2 minutes each) Duration of each session: 35-55 min. Intensity: 2 mth: 50-85% VO2 peak, 2 wk familiarisation, 8 weeks training, 3/wk, 55 min each Food diaries. exercise + branched chain amino acids (BCAA) + placebo vs sedentary + BCAA + placebo
Outcomes	Glycated haemoglobin, weight, Body Mass Index, fasting insulin, fasting glucose, visceral adipose tissue, subcutaneous adipose tissue, VO2 maximum, total cholesterol, high and low density lipoprotein cholesterol, triglycerides
Notes	3 lost to follow up (2 from exercise group and 1 from control)
Allocation concealment	B – Unclear

Study **Raz 1994**

Methods	Study design: Randomised controlled trial Randomisation procedure: Randomised and paired into two groups by age and sex. Allocation concealment: Not stated. Blinding of outcome assessors: Unclear Length of intervention: 12 weeks
---------	---

Characteristics of included studies (Continued)

	Intention-to-treat analysis: Not done
Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Out-patients of Diabetic Clinic n=40 Intervention, 19; control, 19 Mean age: 56.6+/- 6.6 yr Male/female: 26 female, 14 male. Inclusion criteria: persistent hyperglycaemia, despite repeated diet counselling and oral treatment with glibenclamide and metformin. Exclusion criteria: Evidence of ischemic heart disease, elevated systolic blood pressure (>240 mm Hg), could not use bicycle ergometer, wanting to be part of the exercise group only Geographical location: Israel
Interventions	Intervention: Exercise Times per week: 3 group sessions (2 under direct supervision of trainer, 1 unsupervised) Duration of each session: about 50 minutes. Intensity: moderate aerobic exercise. Compliance assessed by a diary. Control: Same lifestyle as before. Diet and lifestyle questionnaire once monthly. Running, rowing and cycling. Swimming or cycling were the unsupervised sessions.
Outcomes	Glycated haemoglobin, triglycerides, VO ₂ maximum, Body Mass Index, total cholesterol, HDL-C, fasting glucose, fructosamine, resting heart rate
Notes	1 in control group had a stroke, 1 in intervention group did not attend many meetings and missed blood tests. There was a post-intervention follow-up one year after the study ended
Allocation concealment	B – Unclear

Study

Ronnemaa 1986

Methods	Study design: Randomised controlled trial Randomisation procedure: randomly divided, no other information. Allocation concealment: not stated Blinding of outcome assessors: unclear Length of trial: 4 months Intention to treat: Not done
Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Community n=30 Mean age: 52.5(45-60) years Male/female: 20 male, 10 female (10 m /5 f per group). Other characteristics: Mean duration of diabetes 7.1 (1-13) years, Medication: sulphonylureas n=18, sulphonylureas + metformin n=10 Baseline characteristics: Reported Geographical location: Finland
Interventions	Intervention: Exercise Times per week: 5-7 Duration of each session: at least 45 minutes. Intensity: exercise at 70%VO ₂ max (walking, jogging or skiing). Common exercise session every third week. Compliance assessed from diaries kept by the participants Comparison intervention: No instructions concerning exercise. Compliance assessed by diaries. Control group received no instructions on exercise
Outcomes	Glycated haemoglobin, triglycerides, fasting plasma insulin, oral glucose tolerance test, VO ₂ max, body mass, total cholesterol, HDL-cholesterol, Apo-lipoprotein A1, Apo-lipoprotein B
Notes	Not intention to treat Number analysed: intervention,13; control, 12. Dropouts explained (Intervention: 1 sent to hospital and put on insulin, 1 had no motivation to exercise. Control: 3 excluded because they altered their oral antidiabetic medication). Further different outcomes from this same experiment in Ronnemaa 1988.

Characteristics of included studies (Continued)

Allocation concealment B – Unclear

Study	Tessier 2000
Methods	Study design: Randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 16 weeks Intention-to-treat analysis: No
Participants	Diagnosis: Non-insulin dependent diabetes mellitus n = 45 Intervention 24 (5 lost to followup); control 21 (1 lost to followup) Setting: Community Mean age: 65 years Male/female: Number analysed Exercise group 19 (12 males, 7 females), Control group 20 (11 men, 9 females) Other characteristics: Stable pharmacological treatment in 3 months, no insulin injections or oral steroids, Caucasian Medications: exercise group: glyburide 10/19, metformin 14/19. control group: glyburide 12/20, metformin 15/20 Baseline characteristics: Reported Geographical location: Canada
Interventions	Intervention: Exercise Times per week: 3 supervised Duration: Each session also included 20 minutes resistance training (2 sets of 20 repetitions) Intensity: walking (from less than 60%VO ₂ max for the first 4 weeks, then 60-79% VO ₂ max for the next 12 weeks)
Outcomes	Glycated haemoglobin, fructosamine, fasting glycaemia and insulinaemia, areas under the glycaemia and insulinaemia curves, Body Mass Index, treadmill test, weight, attitudes
Notes	
Allocation concealment	B – Unclear

Study	Tsujiuchi 2002
Methods	Study design: Randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 4 months Intention-to-treat analysis: Not done
Participants	Diagnosis: Non-insulin dependent diabetes mellitus Setting: Community n = 26 (Intervention n = 16; Control n = 10) Mean Age: intervention 65.3 +/- 7.7 years, control 59.1 +/- 9.0 years Male/female: not stated Other characteristics: pharmacotherapy was not modified Baseline characteristics: Reported Geographical location: Japan
Interventions	Intervention: Exercise: Qi-gong Times per week: 1 Duration of each session: 120 minutes Intensity: Moderate
Outcomes	Glycated haemoglobin
Notes	Cross over trial but only pre-cross over data is presented in this review. 10 of the original subjects were 'excluded from the analysis' for a 'variety of reasons'.

Characteristics of included studies (Continued)

Allocation concealment B – Unclear

Study	Wing 1988b
Methods	Study design: Randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 10 weeks Intention-to-treat analysis: Not done
Participants	Diagnosis: Non-insulin dependent diabetes mellitus n = 30 Setting: Community Mean age: intervention 56 +/- 6 years, control 55 +/- 7 years Male/female: 9 male, 21 female Baseline characteristics: Reported Geographical location: USA
Interventions	Intervention: Exercise Times per week: 4 Duration of each session: 60 minutes. Intensity: moderate aerobic exercise. With standard diet. Comparison group: Standard diet only
Outcomes	Glycated haemoglobin, weight, Body Mass Index, triglycerides, total cholesterol, HDL-cholesterol, blood pressure, fasting insulin, fasting glucose
Notes	Different experimental groups to Wing 1988 (a)
Allocation concealment	B – Unclear

Study	Yeater 1990
Methods	Study design: Randomised controlled trial Randomisation procedure: not stated Allocation concealment: Unclear Blinding of outcome assessors: Unclear Length of intervention: 2 months Intention-to-treat analysis: Yes
Participants	Diagnosis: Non-insulin dependent diabetes mellitus n = 16 Setting: Community Mean age: 57 +/- 8 years Male/female: 7 male, 9 female Other characteristics: Diabetes present 11 +/- 9 years Medications oral hypo-glycaemic agents n=12 Baseline characteristics: Reported Geographical location: USA
Interventions	Intervention: Exercise Times per week: 3 Duration of each session: 40-45 minutes. Intensity: low-intensity aerobic exercise.
Outcomes	Glycated haemoglobin, weight, body mass, triglycerides, total cholesterol, HDL-cholesterol, blood pressure, VO2maximum, resting heart rate, insulin, glucose
Notes	Results data for the control group not provided

Allocation concealment B – Unclear

VO₂max = maximal oxygen uptake

RM - repetition maximum

HDL - high density lipoprotein

LDL - low density lipoprotein

Characteristics of excluded studies

Study	Reason for exclusion
Agurs-Collins 1997	Includes a dietary co-intervention in the exercise intervention group, that has not been applied equally to the comparison group.
Biermann 1986	Trial duration (4 weeks) is less than the 8 week minimum trial duration required for inclusion.
Blonk 1994	Not randomised. Includes a co-intervention of behavioural modification, which has not also been included in the comparison group
Bogardus 1984	Not able to separate the participants with non-insulin dependent diabetes mellitus from those with impaired glucose tolerance. People with impaired glucose tolerance were exclusions in our review.
Dunstan 1997	Control group was also involved in systematic exercise.
Ferrier 2004	Exercise intervention was not supervised objectively.
Fujii 1982	Not randomised; has diet as a co-intervention.
Honkola 1997	Not randomised.
Ishii 1998	Not a randomised controlled trial. The duration of the trial (4-6 weeks) is less than the 8 week minimum trial duration required.
Kaplan 1985	Control group received an education intervention, which was not also given to the intervention group
Kaplan 1987	Control group received an education intervention, which was not also given to the intervention group
Khan 1995	Not randomised.
Lehmann 1995	Not randomised.
Ligtenberg 1997	The supervised duration of the trial (6 weeks) is less than the 8 week minimum trial duration. Thereafter, there was only 'encouragement', not organised supervision.
Samaras 1997	This is a 'health promotion model' with a co-intervention of support; the exercise prescription is unclear
Skarfors 1987	Not randomised (controlled clinical trial - original intention was to randomly allocate, but this was not done)
Vanninen 1992	The exercise intervention group received a co-intervention of intensified diet education during the intervention period, and this was not also provided to the control group
Verity 1989	This study does not report any of the primary outcomes outlined in this review. The baseline characteristics of the participants appear to be different: e.g. participants in the exercise group have a body mass index, classed as overweight; while the control group have a body mass index classed as obese.
Wing 1988a	The control group was also involved in systematic exercise (Study 1). Therefore, as both the control and the intervention groups included exercise, the study could not be included.
Yamanouchi 1995	Not randomised. Subjects not randomised to groups, but 'assigned to one of two groups matched with respect to age, sex and body mass index'.

ADDITIONAL TABLES

Table 01. Search strategy

Electronic searches

Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign (\$) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.

Search for Diabetes mellitus, type 2

- (1) exp diabetes mellitus, non-insulin-dependent/
 - (2) exp insulin resistance/
 - (3) impaired glucose toleranc\$.tw.
 - (4) glucose intoleranc\$.tw.
 - (5) insulin\$ resistanc\$.tw.
 - (6) exp obesity in diabetes/
 - (7) (obes\$ adj diabet\$).tw.
 - (8) (MODY or NIDDM).tw.
 - (9) (non insulin\$ depend\$ or noninsulin\$ depend\$ or noninsulin?depend\$ or non insulin?depend\$).tw.
 - (10) ((typ\$ 2 or typ\$ II) adj diabet\$).tw.
 - (11) ((keto?resist\$ or non?keto\$) adj diabet\$).tw.
 - (12) ((adult\$ or matur\$ or late or slow or stabl\$) adj diabet\$).tw.
 - (13) (insulin\$ defic\$ adj relativ\$).tw.
 - (14) pluri?metabolic\$ syndrom\$.tw.
 - (15) 1or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
 - (16) exp diabetes insipidus/
 - (17) diabet\$ insipidus.tw.
 - (18) 16 or 17
 - (19) 15 not 18
- Search for Exercise
- (20) exercise.tw.
 - (21) physical activity.tw.
 - (22) exertion.tw.
 - (23) physical fitness.tw.
 - (24) walking.tw.
 - (25) weight lifting.tw.
 - (26) strength training.tw.
 - (27) resistance training.tw.
 - (28) circuit weight training.tw.
 - (29) exercise or exertion or physical education and training or physical fitness or sports.sh.
 - (30) sports.tw.
 - (31) 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
- Filter for randomized controlled trials*
- (32) randomized-controlled trial.pt.
 - (33) controlled-clinical trial.pt.
 - (34) randomized-controlled-trials.sh.
 - (35) random allocation.sh.
 - (36) double-blind method.sh.
 - (37) single-blind method.sh.
 - (38) 32 or 33 or 34 or 35 or 36 or 37
 - (39) animal.sh.

Table 01. Search strategy (Continued)

Electronic searches

- (40) human.sh.
- (41) 39 not 40
- (42) 38 not 41
- (43) clinical trial.pt.
- (44) exp clinical trials/
- (45) (clinic\$ adj25 trial\$).tw.
- (46) ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (mask\$ or blind\$)).tw.
- (47) Placebos.sh.
- (48) placebo\$.tw.
- (49) random\$.tw.
- (50) research design.sh.
- (51) (latin adj square).tw.
- (52) 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51
- (53) 52 not 41
- (54) 53 not 42
- Filter for systematic reviews and meta-analyses
- (55) exp meta-analysis/
- (56) exp Review Literature/
- (57) meta-analysis.pt.
- (58) review.pt.
- (59) 55 or 56 or 57 or 58
- (60) letter.pt.
- (61) comment.pt.
- (62) editorial.pt.
- (63) historical-article.pt.
- (64) 60 or 61 or 62 or 63
- (65) 59 not 64
- (66) ((systematic\$ or quantitativ\$ or methodologic\$) adj (review\$ or overview\$)).tw.
- (67) meta?anal\$.tw.
- (68) (integrativ\$ research review\$ or research integration\$).tw.
- (69) quantitativ\$ synthes\$.tw.
- (70) (pooling\$ or pooled analys\$ or mantel\$ haenszel\$).tw.
- (71) (peto\$ or der?simonian\$ or fixed effect\$ or random effect\$).tw.
- (72) 66 or 67 or 68 or 69 or 70 or 71
- (73) 65 or 72
- (74) limit 73 to human [Limit not valid in: Pre-MEDLINE; records were retained]
- (75) 19 and 31 and 54
- (76) 19 and 31 and 74
- (77) 75 or 76

HANDSEARCHES

The reference lists of review articles and included studies were handsearched to locate other potentially eligible studies.

FURTHER SEARCH STRATEGIES

Other potentially eligible studies were sought through experts in the field.

* Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. *International Journal of Epidemiology* 2002;31:150-3.

Table 02. Study Quality

Study	At Baseline	Randomisation	Allocation Concealed	Intention to treat	Assessor blinding	Losses accounted for
Baldi 2003	Similar	Yes	Not reported	Yes	Not reported	No losses
Cuff 2003	Similar	Yes	Not reported	Yes	Not reported	No losses
Dela 2004	Similar	Yes, by drawing lots	Not reported	Yes	Not reported	No losses
Dunstan 1998	Similar	Yes	Not reported	Not done	Not reported	Reasons given
Dunstan 2002	Similar	Yes	Not reported	Not done	Not reported	Reasons given
Loimaala 2003	Similar	Yes	Not reported	Not done	Not reported	Reason given
Maiorana 2002	Similar	Yes	Not reported	Yes	Not reported	No losses
Mourier 1997	Similar	Yes	Not reported	Not done	Not reported	No reason given
Raz 1994	Similar	Yes	Not reported	Not done	Not reported	Reasons given
Ronnemaa 1986	Similar	Yes	Not reported	Not done	Not reported	Reasons given
Tessier 2000	Similar	Yes	Not reported	Not done	Not reported	Reasons given
Tsujiuchi 2002	Similar	Yes	Not reported	Not done	Not reported	No reasons given ('variety of reasons')
Wing 1988b	Similar	Yes	Not reported	Not done	Not reported	No reasons given
Yeater	Plasma triglyceride concentrations were higher in the exercise group. No other baseline differences	Yes	Not reported	Yes	Not reported	No losses

Table 03. Quorum Diagramme**Papers Excluded**

Potentially relevant RCTs identified and screened for retrieval (n = 2101)

Papers excluded (n = 2003)

These papers were excluded because the abstracts revealed that the studies were not relevant to the topic of the review.

Papers retrieved for more detailed evaluation (n = 98)

Papers excluded (n = 63)

After full papers had been retrieved and assessed, those on prevention, those with co-interventions, or in which the type 2 diabetes participants were indistinguishable from insulin impaired or normo-glycaemic participants, were excluded. Main reasons for exclusion were: exercise was not the sole intervention, articles were reviews, studies did not compare similar groups, e.g. only one group had type 2 diabetes, all participants did not have type 2 diabetes, the intervention was less than eight weeks, the paper was on prevention rather than treatment of type 2 diabetes, the study had no control group or the

Table 03. Quorum Diagramme (Continued)

Papers Excluded

study had no randomisation

Potentially appropriate RCTs to be included in the meta-analysis (n = 35)

RCTs excluded from meta-analysis (n = 21)

Reasons: information provided by authors resulted in exclusion for this review, e.g. data for participants with impaired glucose tolerance could not be separated from those with diabetes type 2; control group intervention included exercise also; one had 6 weeks of supervised exercise, and thereafter 'encouraged by phone'; diet co-intervention was used, trial was not randomised, or insufficient data were provided

RCTs included in meta-analysis (n = 14)

RCTs withdrawn (n = 0)

RCTs with usable information (n = 14).

Outcome measures included:

Glycated Haemoglobin n = 13

Visceral adipose tissue n = 2

Subcutaneous adipose tissue n = 2

Body mass n = 10

Triglycerides n = 5

Maximal exercise capacity n = 3

Systolic blood pressure n = 4

Diastolic blood pressure n = 3

Fasting plasma glucose concentration n = 9

Insulin (fasting concentration) n = 7

Body Mass Index n = 7

Total cholesterol n = 5

HDL-cholesterol n = 5

LDL-cholesterol n = 3

Apo-lipoprotein A1 n = 2

Apo-lipoprotein B n = 2

Fat free mass n = 1

Insulin sensitivity (area under the insulinaemia curve) n = 1

Attitude to diabetes n = 1

Glycaemia (area under the curve) n = 1

Fructosamine n = 1

KITT constant (insulin tolerance test) n = 1

Fat mass n = 1

Table 04. Original data

Study ID / Outcome	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
01.01 Glycated haemoglobin (%)						
Baldi 2003	9	8.40	1.80	9	8.40	1.80
Cuff 2003	10	6.80	1.26	9	6.87	1.20
Dela 2004	9	8.20	1.80	7	8.50	1.59
Dunstan 1998	11	8.00	1.66	10	8.30	2.21
Dunstan 2002	16	6.90	1.00	13	7.10	1.10

Loimaala 2003	24	7.60	1.40	25	8.30	1.40
Maiorana 2002	16	7.90	1.2	16	8.50	1.6
Mourier 1997	10	6.20	0.63	11	7.70	1.33
Raz 1994	19	11.70	2.60	19	12.90	4.20
Ronnemaa 1986	13	8.60	1.90	12	9.90	1.70
Tessier 2000	19	7.60	1.20	20	7.80	1.50
Tsujiuchi 2002	16	7.33	1.09	10	8.17	1.30
Tsujiuchi 2002	16	7.33	1.09	10	8.17	1.30
Wing 1988: 2nd study	13	8.20	1.08	15	9.00	1.16

01.02 Visceral adipose tissue (cm2)

Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Cuff 2003	10	224.80	23.40	9	258.70	36.00
Mourier 1997	10	80.40	22.14	11	134.90	33.83

01.03 Subcutaneous adipose tissue (cm2)

Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Cuff 2003	10	446.90	48.70	9	566.70	27.00
Mourier 1997	10	186.70	44.59	11	260.30	71.64

01.04 Body Mass (kg)

Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Baldi 2003	9	114.00	12.30	9	110.90	22.20
Cuff 2003	10	86.60	12.33	9	97.60	19.50
Dela 2004	9	97.00	12.00	7	92.00	18.52
Dunstan 1998	11	83.20	12.30	10	83.70	12.00
Dunstan 2002	16	86.20	10.90	13	86.40	12.10
Maiorana 2002	16	88.70	17.60	16	88.70	17.60
Mourier 1997	10	83.80	12.33	11	84.20	15.26
Ronnemaa 1986	13	83.20	19.50	12	83.30	12.40
Tessier 2000	19	83.00	17.60	20	79.50	14.60
Wing 1988: 2nd study	13	94.80	21.30	15	96.40	19.74

01.05 Triglycerides (mmol/litre)

Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Maiorana 2002	16	2.20	1.20	16	2.70	1.60
Mourier 1997	8	1.79	1.08	8	2.33	0.63
Raz 1994	19	1.90	0.70	19	2.20	0.06

Table 04. Original data (Continued)

Study ID / Outcome	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Ronnemaa 1986	13	1.91	0.97	12	1.75	0.62
Wing 1988: 2nd study	13	1.42	0.69	15	1.64	0.74
01.06 Maximal exercise capacity (VO2max)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Loimaala 2003	24	33.80	5.50	25	31.80	6.60
Mourier 1997	10	32.40	4.11	11	23.00	4.97
Ronnemaa 1986	13	29.30	6.20	12	25.90	6.70
01.07 Systolic blood pressure (mmHg)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Dunstan 1998	11	127.00	9.96	10	127.00	12.64
Dunstan 2002	16	138.30	17.80	13	144.50	15.50
Loimaala 2003	24	138.00	16.00	25	144.00	14.00
Wing 1988: 2nd study	13	130.00	18.05	15	135.00	23.22
01.08 Diastolic blood pressure (mmHg)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Dunstan 1998	11	73.00	6.64	10	72.00	6.32
Dunstan 2002	16	73.60	8.80	13	74.10	6.40
Wing 1988: 2nd study	13	83.00	7.22	15	85.00	15.48
01.09 Fasting plasma glucose concentration (mmol/litre)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Baldi 2003	9	11.40	2.40	9	11.00	3.00
Dela 2004	9	10.90	3.60	7	12.10	3.44
Dunstan 1998	11	9.40	2.66	10	9.80	4.11
Maiorana 2002	16	9.80	2.00	16	12.00	2.00
Mourier 1997	10	9.50	1.58	11	8.60	1.66
Raz 1994	19	10.20	3.30	19	12.30	4.40
Ronnemaa 1986	13	10.50	4.40	12	11.20	2.20
Tessier 2000	19	9.20	2.50	20	8.40	2.30
Wing 1988: 2nd study	13	8.40	1.81	15	9.20	2.71
01.10 Insulin (fasting concentration) (pmol/litre)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD

Table 04. Original data (Continued)

Study ID / Outcome	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Baldi 2003	9	21.10	12.30	9	30.90	22.50
Dela 2004	9	134.00	81.00	7	131.00	68.79
Dunstan 1998	11	63.10	41.83	10	93.80	39.82
Mourier 1997	10	21.10	7.90	11	21.90	12.60
Ronnemaa 1986	13	15.40	10.80	12	15.50	8.20
Tessier 2000	19	17.10	8.70	20	17.00	6.90
Wing 1988: 2nd study	13	18.30	11.19	15	17.60	16.25

01.11 Body Mass Index (kg/m²)

Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Dela 2004	9	31.00	3.00	7	30.00	5.29
Dunstan 1998	11	28.10	2.65	10	30.40	3.48
Loimaala 2003	24	28.90	3.80	25	29.80	3.70
Maiorana 2002	16	29.60	13.20	16	29.60	13.60
Mourier 1997	10	30.60	1.90	11	30.00	5.31
Raz 1994	19	31.50	4.30	19	30.60	4.20
Tessier 2000	19	30.60	5.40	20	29.40	3.80

Table 05. Original data (continued)

Study ID / Outcome	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
01.12 Total cholesterol (mmol/litre)						
Maiorana 2002	16	4.60	0.80	16	4.60	0.80
Mourier 1997	8	5.34	1.42	8	5.40	1.16
Raz 1994	19	5.60	1.00	19	6.00	1.00
Ronnemaa 1986	13	6.37	0.90	12	6.10	1.00
Wing 1988: 2nd study	13	4.21	0.83	15	4.44	0.62
01.13 HDL-cholesterol (mmol/litre)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Maiorana 2002	16	1.10	0.40	16	1.00	0.40
Mourier 1997	8	1.02	0.17	8	1.12	0.18
Raz 1994	19	1.10	0.30	19	1.10	0.30
Ronnemaa 1986	13	1.29	0.36	12	1.26	0.31

Table 05. Original data (continued) *(Continued)*

Study ID / Outcome	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Wing 1988: 2nd study	13	0.94	0.18	15	0.96	0.19
01.14 LDL-cholesterol (mmol/litre)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Maiorana 2002	16	2.50	0.80	16	2.40	0.80
Mourier 1997	8	4.34	1.39	8	4.29	1.16
Ronnemaa 1986	13	4.29	0.87	12	4.11	0.90
01.17 RFI (risk factor index = total cholesterol/HDL)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Mourier 1997	8	5.24	1.59	8	4.82	1.34
Raz 1994	19	5.09	1.30	19	5.45	1.30
Ronnemaa 1986	13	4.94	1.26	12	4.80	1.31
Wing 1988: 2nd study	13	4.48	1.01	15	4.65	0.81
01.18 Fat free mass (kg)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Baldi 2003	9	76.90	3.30	9	70.60	9.00
01.19 Insulin sensitivity (AUC insulinaemia)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Tessier 2000	19	400.00	212.00	20	269.00	131.00
01.24 Fat mass (kg)						
Study ID	Exercise N	Exercise Mean	Exercise SD	Control N	Control Mean	Control SD
Baldi 2003	9	37.00	10.50	9	40.30	18.90

ANALYSES**Comparison 01. Exercise vs no exercise**

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Glycated haemoglobin (%)	13	361	Weighted Mean Difference (Fixed) 95% CI	-0.62 [-0.91, -0.33]
02 Visceral adipose tissue (cm ²)	2	40	Weighted Mean Difference (Fixed) 95% CI	-45.54 [-63.76, -27.31]
03 Subcutaneous adipose tissue (cm ²)			Weighted Mean Difference (Fixed) 95% CI	Subtotals only
04 Body Mass (kg)	10	248	Weighted Mean Difference (Fixed) 95% CI	-0.04 [-3.83, 3.76]
05 Triglycerides (mmol/litre)	5	139	Weighted Mean Difference (Fixed) 95% CI	-0.25 [-0.48, -0.02]
06 Maximal exercise capacity (VO ₂ max)(ml/(kg*min))	3	95	Weighted Mean Difference (Fixed) 95% CI	4.84 [2.55, 7.12]
07 Systolic blood pressure (mmHg)	4	127	Weighted Mean Difference (Fixed) 95% CI	-4.16 [-9.46, 1.14]

08 Diastolic blood pressure (mmHg)	3	78	Weighted Mean Difference (Fixed) 95% CI	-0.13 [-3.70, 3.45]
09 Fasting plasma glucose concentration (mmol/L)	9	238	Weighted Mean Difference (Fixed) 95% CI	-0.45 [-1.09, 0.18]
10 Insulin (fasting concentration (pmol/litre)	7	168	Weighted Mean Difference (Fixed) 95% CI	-0.71 [-4.13, 2.71]
11 Body Mass index (kg/m ²)	7	216	Weighted Mean Difference (Fixed) 95% CI	-0.21 [-1.35, 0.93]
12 Total cholesterol (mmol/l)	5	139	Weighted Mean Difference (Fixed) 95% CI	-0.11 [-0.41, 0.18]
13 HDL-cholesterol (mmol/l)	5	139	Weighted Mean Difference (Fixed) 95% CI	-0.02 [-0.10, 0.06]
14 LDL-cholesterol (mmol/l)	3	73	Weighted Mean Difference (Fixed) 95% CI	0.12 [-0.29, 0.53]

INDEX TERMS

Medical Subject Headings (MeSH)

Blood Glucose [metabolism]; Body Mass Index; Diabetes Mellitus, Type 2 [*metabolism; *therapy]; Exercise [*physiology]; Hemoglobin A, Glycosylated [*metabolism]; Obesity [therapy]; Randomized Controlled Trials; Subcutaneous Fat [pathology]; Weight Loss

MeSH check words

Female; Humans; Male

COVER SHEET

Title	Exercise for type 2 diabetes mellitus
Authors	Thomas DE, Elliott EJ, Naughton GA
Contribution of author(s)	Diana Thomas: co-ordinated the review process, searched for trials, screened the search results, assessed the trials for quality, extracted data, analysed data, developed the review and took the primary role in writing it Elizabeth Elliott: screened search results, assessed the trials for quality, analysed data, provided a clinical perspective, developed the review Geraldine Naughton: searched for trials, screened search results, assessed the quality of trials, extracted data, analysed data
Issue protocol first published	2004/2
Review first published	2006/3
Date of most recent amendment	24 May 2006
Date of most recent SUBSTANTIVE amendment	24 May 2006
What's New	Information not supplied by author
Date new studies sought but none found	Information not supplied by author
Date new studies found but not yet included/excluded	Information not supplied by author
Date new studies found and included/excluded	Information not supplied by author
Date authors' conclusions section amended	Information not supplied by author
Contact address	Dr Diana Thomas


Scientific Director
 CEBPGAN (Centre for Evidence Based Paediatrics Gastroenterology and Nutrition)
 The University of Sydney, The Children's Hospital at Westmead
 Locked Bag 4001
 Westmead
 NSW 2145
 AUSTRALIA
 E-mail: dianat@chw.edu.au
 Tel: +61 2 98451203
 Fax: +61 2 98453082

DOI 10.1002/14651858.CD002968.pub2
Cochrane Library number CD002968
Editorial group Cochrane Metabolic and Endocrine Disorders Group
Editorial group code HM-ENDOC

GRAPHS AND OTHER TABLES

Analysis 01.01. Comparison 01 Exercise vs no exercise, Outcome 01 Glycated haemoglobin (%)

Review: Exercise for type 2 diabetes mellitus
 Comparison: 01 Exercise vs no exercise
 Outcome: 01 Glycated haemoglobin (%)




Analysis 01.02. Comparison 01 Exercise vs no exercise, Outcome 02 Visceral adipose tissue (cm2)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 02 Visceral adipose tissue (cm2)




Analysis 01.03. Comparison 01 Exercise vs no exercise, Outcome 03 Subcutaneous adipose tissue (cm2)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 03 Subcutaneous adipose tissue (cm2)




Analysis 01.04. Comparison 01 Exercise vs no exercise, Outcome 04 Body Mass (kg)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 04 Body Mass (kg)




Analysis 01.05. Comparison 01 Exercise vs no exercise, Outcome 05 Triglycerides (mmol/litre)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 05 Triglycerides (mmol/litre)




Analysis 01.06. Comparison 01 Exercise vs no exercise, Outcome 06 Maximal exercise capacity (VO2max)(ml/(kg*min))

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 06 Maximal exercise capacity (VO2max)(ml/(kg*min))




Analysis 01.07. Comparison 01 Exercise vs no exercise, Outcome 07 Systolic blood pressure (mmHg)

Review: Exercise for type 2 diabetes mellitus


Comparison: 01 Exercise vs no exercise

Outcome: 07 Systolic blood pressure (mmHg)




Analysis 01.08. Comparison 01 Exercise vs no exercise, Outcome 08 Diastolic blood pressure (mmHg)

Review: Exercise for type 2 diabetes mellitus
 Comparison: 01 Exercise vs no exercise
 Outcome: 08 Diastolic blood pressure (mmHg)



Analysis 01.09. Comparison 01 Exercise vs no exercise, Outcome 09 Fasting plasma glucose concentration (mmol/L)

Review: Exercise for type 2 diabetes mellitus
 Comparison: 01 Exercise vs no exercise
 Outcome: 09 Fasting plasma glucose concentration (mmol/L)




Analysis 01.10. Comparison 01 Exercise vs no exercise, Outcome 10 Insulin (fasting concentration (pmol/litre))

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 10 Insulin (fasting concentration (pmol/litre))




Analysis 01.11. Comparison 01 Exercise vs no exercise, Outcome 11 Body Mass index (kg/m2)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 11 Body Mass index (kg/m2)




Analysis 01.12. Comparison 01 Exercise vs no exercise, Outcome 12 Total cholesterol (mmol/l)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 12 Total cholesterol (mmol/l)




Analysis 01.13. Comparison 01 Exercise vs no exercise, Outcome 13 HDL-cholesterol (mmol/l)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 13 HDL-cholesterol (mmol/l)



Analysis 01.14. Comparison 01 Exercise vs no exercise, Outcome 14 LDL-cholesterol (mmol/)

Review: Exercise for type 2 diabetes mellitus

Comparison: 01 Exercise vs no exercise

Outcome: 14 LDL-cholesterol (mmol/)

